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Abstract 
Recently caspases have received much attention as potential drug targets in the treatment of cancer. 
Procaspase-3, the executioner of apoptosis, was found to be in elevated concentrations in cancer 
cells. Procaspase activating compound 1, PAC-1, induced cell death through activation of caspases 
in a dose dependent manner in cancer cell lines. This prompted us to synthesize 16 PAC-1 
analogues which were tested for their cytotoxic properties in seven cancer cell lines. Two 
compounds, 128 and 130, were equally cytotoxic as PAC-1 in the PC12 cell line. PAC-1 was 
investigated for its toxicity in non-dividing cells; chicken granular neurons, and was established as a 
potential neurotoxin.  
The ortho-formylation reaction employing the MgCl2/Et3N base system has been well established as 
a versatile and environmental benign method. This base system have been employed in the 
syntheses of salicylaldehydes, one-pot procedures and total synthesis of natural products. The 
original ortho-formylation method article by Skattebøl and Hofsløkken has close to 100 citations. 
We have explored the reaction conditions on mono-protected resorcinols and estrogens.  In both 
compound classes, good to high yields were obtained, as well as regioselectivity. The ortho-
formylation of estradiol was used as a key step in the preparation of the anti-cancer agent 2-
methoxyestradiol.  
The phosphate prodrugs of combretastatin A-1 and A-4 are currently in human clinical trials for 
their anti-cancer properties. Even though the solubility problems the combretastatins first faced 
have been solved now, there is still an issue with the isomerization of the cis-olefinic bridge to the 
inactive trans-isomers of the combretastatins. Our laboratory has successfully replaced the bridge 
with the heterocyclic moiety 1,2,3-triazole to produce cis-restricted analogues of CA-1. The 
analogues were subjected to cytotoxicity testing against four cancer cell lines and evaluated for their 
anti-angiogenetic properties. The most cytotoxic triazoles were also tested for their ability to inhibit 
tubulin polymerization. Compound 180 showed equal potency as CA-1 (19) in all the cell lines and 
was equally active as a inhibitor of tubulin polymerization and angiogenesis. These activities are 
most likely, at least in part, due to binding to the colchicine binding site of ,-tubulin, as supported 
by molecular modeling studies. 
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1 Introduction 
1.1 Cancer and chemotherapy 
Cancer is a generic term for a large group of diseases that can affect any part of the body. One 
defining feature of cancer is the uncontrollable growth of abnormal cells, which can then invade 
adjoining parts of the body and spread to other organs through the blood and lymph system. Cancer 
is a leading cause of death worldwide causing 7.6 million deaths in 2008 and it is estimated a 45% 
increase to the year 2030, and will cause over 11 million deaths.1 
1.1.1 Chemotherapy 
Depending on the manifestation of the cancer, the first line of treatments are surgical intervention, 
radio- and chemotherapy, but also included is psychosocial support. Despite the advances in 
pharmaceuticals, chemotherapy is still inadequate in treatment of various forms of cancer, and 
treatments have yet to obtain total remission in all forms of cancer. Classical anti-cancer agents 
focus on achieving increased tumour cytotoxicity based on the different proliferating activity 
between normal and malignant neoplastic cells. Achieving selectivity has been the Achilles heel of 
conventional chemotherapeutics and the consequence is embodied in the harsh side-effects 
observed. Recently, studies that specifically target the genes, proteins, receptors and molecular 
pathways that regulate the growth and survival of tumours have gained attention.2 Anti-cancer drug 
design and development has been inspired by these recent discoveries of potential drug targets. 
Consequently the search for magic bullets that improves the efficacy and diminishes the side effects 
of cancer therapy continues.  
1.2 Anti-cancer agents 
1.2.1 General  
Though cytotoxic compounds have been present in plant derived traditional medicine for thousands 
of years, the first study and identification of a cytotoxic compound was performed in the laboratory 
of Paul Ehrlich. Ehrlich received the Nobel price in physiology/medicine in 1908.3,4 He first used 
the term chemotherapeutic agents and coined the expression “magic bullet” in regards for the 
strived for quality of a potential drug. The term implies that the compound will only affect a 
predefined target and nothing else. 
Today, 100 years hence, there are numerous antineoplastic agents used in clinic and in clinical trials. 
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Even now there are numerous potential magic bullets being synthesized in round bottomed flasks 
around the world. Science is still a long way short of understanding all the underlying mechanisms 
in the body by which the therapeutic agents work, but every bit and piece of knowledge is puzzled 
together and paving the way towards “the magic bullet”. 
1.2.2 Antineoplastic agents and their biological mechanism 
Antineoplastic agents have been divided into categories according to their mechanism of action or 
structural similarities. According to the anatomical therapeutic chemical (ATC) register they are 
divided into five groups L01A-D and X corresponding to alkylating agents, antimetabolites, plant 
alkaloids and other natural products, cytotoxic antibiotics and other antineoplastic agents (Figure 
1).5 
 
 
Figure 1 Selected antineoplastic agents from the ATC register. 
 
Alkylating agents, such as 1 and 2, react covalently with the guanine base of DNA, at the 7-nitrogen 
atom of the purine ring. This type of alkylation hinders the cell in replicating successfully. 
Alkylating agents are also cytotoxic to normal cells in particular cells that divide frequently.6 
Antimetabolites, such as 3-5, are used in cancer treatment, as they interfere with biosynthesis of 
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DNA and therefore cell division and the growth of tumours. The interference is caused by the 
inhibition of an enzyme in the biosynthetic pathway of the metabolite or from incorporation, as a 
false building block, into vital proteins and polynucleosides.6 The mechanisms of action of the 
cytotoxic antibiotics, doxorubicin (6), are not fully understood. 6 act by interchelation of DNA, 
crosslinking of DNA, inhibition of macromolecular biosynthesis and as DNA strandbreaker. The 
class of other antineoplastic agents is a diverse group of drugs that are inhibitors of type I and II 
topoisomerase, crosslinkers of DNA and as monoclonal antibodies. Compounds 7 and 8 are two 
examples.5,6 
Docitaxel (9), vinblastine (10) and podophyllotoxin block cell division by targeting microtubule 
function by either a stabilizing or a destabilizing mechanism. All of the compounds 9-11 are 
considered microtubule binding agents (MBA), and each bind to a specific binding site. The taxoid 
and podophyllotoxin/colchicine sites are known while scientists are still searching for the exact 
vinca alkaloid site.7,8 Microtubules are vital for cell division, and, without them, cell division cannot 
occur.9 Podophyllotoxin is used in production of two other cytostatic drugs, etoposide (11) and 
teniposide. The exact mechanism of action of podophyllotoxin and derivatives is not yet known, but 
it involves inhibiting the catalytic activity of DNA topoisomerase II and in some cases ambiguous 
mechanisms.9 The search for new MBAs continues and currently several compounds are under 
investigation as potential drug candidates.10 
Studies have shown that most MBAs have antivascular effects from anti-angiogenetic or vascular 
disrupting activities, or both.11 Disrupting the blood supply leads to starvation of the tumour, 
consequently this prevents growth and induces necrosis. There are two different biological 
pathways that affect tumour vasculature: inhibition of angiogenesis and the formation of new 
vessels from pre-existing ones, and a vascular disrupting pathway that selectively destroys the 
already formed tumour vascular bed.11 The anti-angiogenetic approach exerts mainly a cytostatic 
effect, while vascular disrupting agents induce tumour necrosis and vessel collapse inside the 
tumour. However, induction of tumour necrosis by a single administration does not lead to tumour 
eradication, as a rim of viable tumour cells survives and proliferates in the periphery of the 
tumour.11  
1.3 Procaspase-3 and caspase-3 activating compounds 
1.3.1 Caspases 
In multicellular organisms, homeostasis is maintained through a balance between cell proliferation 
and cell death. Owing to its role in the elimination of virally infected and damaged cells, apoptosis 
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has a central role in the prevention of diseases. Hyper or hypo activity of caspases (cysteinyl 
aspartate proteinases) leads to a host of pathologies, including cancer, autoimmune diseases, sepsis, 
immunodeficiency and neurodegenerative disorders.12 The role of caspases in cell homeostasis is 
more important than what one might first imagine; knockout mice without either one of the genes 
for caspase-3, -8 and -9 die prenatally or postnatally mostly due to defective brain development.12 A 
dysfunction in the apoptotic cascade might be one of the factors that lead to aberrant proliferation of 
tumour cells as the cell do not self eliminate when proapoptotic signals are triggered. 
The caspases are a family of cysteine proteases, enzymes that cleave their substrates following an 
aspartate residue. There are 15 identified mammalian caspases and all their biological roles are yet 
to be fully elucidated.12-17 They are synthesized as inactive zymogens consisting of a prodomain, a 
large p20 and a small p10 subunit. The size of the prodomain varies, and can be used to divide the 
caspases into two different main groups, the initiator caspases (caspase-1, -2, -4, -5 and 8-12) and 
the effector caspases (caspase-3, -6 and -7). The caspases play a central role in the initiation and 
execution phases of apoptosis.12 Upon activation, these enzymes cleave specific substrates and 
thereby mediate many of the typical biochemical and morphological changes in apoptotic cells, 
such as cell shrinkage, chromatin condensation, DNA fragmentation and plasma membrane 
blebbing.12-16 Activation of the zymogens by proteolytic cleavage separates the large and small 
subunits and removes the prodomain. The active caspases consist of a homodimer, with each 
monomer of a large and a small subunit (Figure 2).12  
 
 
Figure 2 The structure and activation of caspases. (a) The prodomain is cleaved from the caspase and the monomer 
forms the active homodimer with a second cleaved caspase. Adapted from reference.14 (b) X-ray structure of active 
caspases-7 (pdb: 1K88),18 p10 black and p20 grey.  
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There are two general modes of caspase activation, the extrinsic (death receptor pathway) and 
intrinsic (internally initiated by damage and stress) (Figure 3). The extrinsic pathway is activated by 
extracellular stimulus that is transmitted to the cytosol by transmembrane death receptors that 
belong to the family of tumour necrosis factor receptors. Recruitment of procaspase-8 and -10 as 
well as other ligands at this receptor leads to the formation of a death-inducing signalling complex 
(DISC) that triggers maturation of both initiators. Ultimately, procaspase-3 (pCasp-3) and 
procaspase-7 are activated by the mature caspases-8 and -10.17 The intrinsic pathway can be 
triggered by stimuli such as DNA damage and cytotoxic drugs or UV-radiation. Different damages 
or stress signals promote, via protein messengers, the mitochondria to release cytochrome c. 
Cytosolic cytochrome c, apoptotic protease activating factor 1 (Apaf-1) and the cofactor dATP/ATP 
then form a multimeric protein complex called the apoptosome. Procaspase-9, which is activated 
through an apoptosome-induced conformational change, further processes the downstream 
caspases, such as pCasp-3 and procaspase-7, to carry out the eventual execution of apoptosis.17 
 
 
Figure 3 The biological activation cascade of pCasp-3. Adopted from reference.19  
1.3.2 Procaspase-3 and caspase-3 
pCasp-3 together with procaspase-6 and -7 are the effector caspases, also known as executioner 
caspases, as they initiate cellular suicide apoptosis. pCasp-3 is activated by either caspase-8, -9 or -
10 upstream in the apoptotic cascade as well as autocatalytic cleavage. This cleavage is also 
sensitive to acidification as its dormancy is guarded by an triaspartic acid “safety catch”.20 
Furthermore, zinc plays an important role in apoptosis as a natural inhibitor of caspase-3 activity.21-
23 X-linked inhibitor of apoptosis (XIAP) is an endogenous inhibitor that binds reversibly to 
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caspase-3 and -7.24,25 Numerous small molecules and peptides that are inhibitors of caspases-3 have 
been synthesized.26-31 
Cells from certain types of cancerous tissues have elevated concentrations of pCasp-3. A study of 
primary isolates from 20 individuals with colon cancer, showed that on average, pCasp-3 is elevated 
six-fold in such isolates relative to adjacent noncancerous tissue.20 In addition, pCasp-3 
concentrations are elevated in certain neuroblastomas,32 lymphomas,33 leukemias,34 melanomas,35 
and liver cancers.36 A systematic evaluation of pCasp-3 concentrations revealed that particular lung, 
melanoma, renal and breast cancers show greatly enhanced concentrations of pCasp-3 in the panel 
of 60 cell lines used by the National Cancer Institute.37  
1.3.3 Procaspase activating compounds 
In October 2006 Hergenrother and co-workers published an article that claimed to have identified 
and synthesized the first direct procaspase activating compound-1 (Figure 4, PAC-1, 12). Based on 
the observations that cancer cells have elevated pCasp-3 concentration levels, they envisioned a 
personalized anti-cancer therapy, based on the direct activation of pCasp-3.38 With the aid of high 
throughput screening, approximately 20500 structurally diverse small molecules were evaluated for 
pCasp-3 activation in vitro.  
 
 
Figure 4 Procaspase activating compound 1 (PAC-1) and a second active derivative. 
 
Only one of the compounds screened activated pCasp-3 in a dose dependent manner with an EC50 
value of 0.22 µM. Compound 13, which was prepared after the discovery of PAC-1 (12), was half 
as active with an EC50 = 0.43 µM. PAC-1 (12) was less active against pCasp-3 safety catch mutants 
where the three aspartic acid residues were replaced with alanine (D3A). The researchers proposed 
that PAC-1 (12) had the ability to donate protons to the triaspartic acids at physiological pH and this 
was the source of its activity. The experiments conducted by the authors verified a correlation 
between relative pCasp-3 concentration and IC50 values in 13 cancer cell lines. The cells containing 
the highest pCasp-3 concentration had the lowest IC50 value and vice versa. Finally, compound 12 
was effective in three distinct mouse models of cancer (one renal and two lung), including two in 
which PAC-1 (12) was administered orally.38 The direct activation of pCasp-3 was disputed by 
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Denault and co-workers since they did not observe cleavage of pCasp-3 to the active caspase-3 by 
compound 12.39,40 
Peter Kovacic recognized that PAC-1 (12) possessed a chelating site for metal binding closely 
related to salicylaldehyde semicarbazones.41 These moieties are known to be avid chelators, as seen 
in structure 14 (Figure 5).42,43 Zinc has been shown to be an important regulator of apoptosis, and 
depletion of cellular zinc by chelation with the compound N,N,N′,N-tetrakis(2-pyridylmethyl) 
ethylenediamine (TPEN, 15) resulted in activation of caspases and apoptotic cell death.21,22,44,45  
 
 
Figure 5 A salicylaldehyde semicarbazone chelating a metal ion (Mn+) and the structure of TPEN. 
 
Hergenrother and co-workers confirmed the assumption made by Kovacic when they published an 
article describing that PAC-1 (12) was capable of chelating zinc(II) with a Kd of 42 nM. The authors 
concluded that PAC-1 (12) activated pCasp-3 and caspase-3 in a dose dependent manner because of 
zinc chelation. Caspase-3 activity was also inhibited by copper(II), cobalt(II), iron(II) ions in 
substoichiometric or stoichiometric quantities, but other ions such as manganese(II), iron(III) and 
magnesium(II) had little impact on caspase-3 activity.46 A structure activity relationship (SAR) 
study was undertaken and derivatives of 12 were evaluated for cytotoxic activity against U937 cells, 
caspase-3 activation and zinc binding (Kd).47 Clear trends were thus apparent from the SAR data: 
(1) PAC-1 derivatives that are unable to bind zinc do not activate caspase-3 in vitro, and do not 
appreciably induce death in U-937 cells in culture. This information suggests that the zinc binding 
capacity of PAC-1 (12) is important for its cell death-inducing properties. (2) The ortho-hydroxy N-
acylhydrazone motif is critical for zinc binding. (3) Virtually all compounds that bind zinc activate 
caspase-3 in vitro and induce death in U-937 cells in culture.47  
Methods have been developed for the characterization of the in vivo and in vitro metabolic profile 
of PAC-1 (12) and for quantification in rat plasma using HPLC and MS.48,49 The same research 
group isolated and characterized the degradation products of 12.50 In an investigation of the 
pharmacokinetic profile as well as a dosing regime in healthy dogs, PAC-1 (12) was found to have 
the properties of a potential anti-cancer drug. Hematologic and non-hematologic tolerability of 48-
hour PAC-1 (12) treatment was within reference values from day 0 to 21. This treatment regimen 
was well tolerated in a large mammalian model (dog) which closely mimics the body size, 
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physiology, and metabolism of humans.51 Despite being apparently well tolerated in dogs, 
compound 12 was established as neurotoxic when injected via the tail vain of C57/BL6 mice. PAC-
1 has a calculated partitioning ratio of 1.0:0.85 between the blood and the brain, suggesting that a 
significant amount of PAC-1 (12) may be entering the central nerve system (CNS) causing 
neurotoxicity. To overcome the neurotoxicity, a sulfonamide analogue of PAC-1 was designed, S-
PAC-1 (16) (Figure 6). Compound 16 showed similar cytotoxicity to PAC-1 (12) against several 
cancer cell lines, had a Kd of 46 nM for zinc chelation and a lower calculated propensity to cross the 
blood-brain barrier (BBB) (blood/brain ratio of 1.0:0.055). It was well tolerated in mice at a dose of 
350 mg/kg and had no detectable neurotoxic effect. 
  
Figure 6 S-PAC-1, less probable than PAC-1 (12) to cross the blood-brain barrier. 
 
On assessment of S-PAC-1 in dogs with lymphoma, only minor adverse events were reported which 
subsided within 48 hours after the end of each treatment cycle. Given the small number of patients 
(dogs, n = 6) included in this study, antitumour activity of S-PAC-1 cannot be conclusively 
determined. At the moment more in vivo studies are needed to establish whether S-PAC-1 (16) 
prospectives as an anti-cancer drug are promising.  
 
 
Figure 7 pCasp-3 activating compounds. 
 
Compound 17 activates pCasp-3/caspase-3 by that a single molecule binds to an allosteric site near 
one active site of the caspase-3 dimer as inhibitor and stabilizes an on-state conformation that 
promotes self-cleavage at the active site of the unoccupied subunit. At high concentrations, 
compound 1541 (17) can inhibit both active sites.  It was cytotoxic against BT549, MDA-MB361, 
HEK293, HeLa, and HCC1954 cell lines.52 Based on a virtual docking protocol, Clark and co-
workers proposed 15 compounds that could bind to the allosteric binding site and stabilize the on-
state conformation of caspase-3. Only compound 18 showed weak activation of pCasp-3 with an 
EC50 in the high µM range.53 None of the compounds in Figure 7 were evaluated for zinc chelation. 
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1.4 Combretastatins 
Combretastatins are a group of natural compounds that have received much attention due to their 
simple structure and their intriguing anti-cancer properties.54-58 Combretastatin A-1 (CA-1, 19) and 
A-4 (CA-4, 20) are the most studied compounds of this group; both exert potent cytotoxicity and 
inhibition of tubulin polymerization in vitro. The compounds 19 and 20 are hampered as drug 
candidates by low aqueous solubility, and CA-4 might isomerize to the less active trans-form. Their 
phosphate salt prodrugs 21 and 22 have been synthesized (Figure 8) and are currently in several 
clinical trials as anti-cancer drugs.56,59-61 Recently, the monophosphate prodrugs of CA-1 were 
synthesized and their cytotoxic activity were comparable to 21.59 
 
 
Figure 8 Combretastatins CA-1, CA-4 and their corresponding phosphate prodrugs CA-1P and CA-4P. 
 
1.4.1 Discovery and identification 
The combretastatins are a group of natural products isolated from the South African willow tree 
Combretum caffrum, a genus known for its medicinal properties in Africa and India. Cytotoxic 
investigation of extracts of the branches, leaves and fruit of this plant lead to the isolation and 
identification of combretastatin (23) by Pettit and co-workers in 1982.62 Combretastatin (23) 
induces astrocyte reversal and growth inhibition of the murine P388 lymphocytic leukaemia cell 
line. It was established as a tubulin polymerization inhibitor and to inhibit the binding of 
[3H]colchicine to tubulin. Moreover, it was an effective antimitotic and stimulated tubulin-
dependent GTP hydrolysis.63 Pettit and co-workers have synthesized racemic and natural 
combretastatin and defined the absolute configuration of the hydroxyl group.64,65 
 
Aside from combretastatin (23) numerous derivatives have been isolated and identified from the C. 
caffrum tree (Figure 9).  
10 
 
 
Figure 9 bisBenzyl derivatives isolated form C. caffrum.62,66-75 
 
The A series are stilbenes, the B series are dihydrostilbenes, several isolated compounds (32-34) 
have not been given a CB number, but never the less they fit into the CB scaffold. The C series are 
phenantrene quinones and the D series macro cyclic lactones. Phenanthrene 38 has not been given 
any abbreviation. 
Five years passed from the isolation of combretastatin before Pettit and co-workers published the 
second paper on the isolation of combretastatin A-1 (19) and B-1 (28) from the stem-wood extract 
of C. caffrum. Both were synthesized, characterized and found to inhibit cell growth of the murine 
P388 cell line as well as inhibit tubulin polymerization and [3H]colchicine binding to tubulin.67 The 
tubulin inhibition activity has been confirmed by others.76 
From the same stem-wood extract of C. caffrum, combretastatin A-4, A-5 and A-6 (20, 26 and 27) 
were found together in a trace fraction. All three compounds were found significantly active against 
the murine L1210 and P388 cell lines. The growth inhibitory effects of CA-4 are comparable to 
CA-1, but is far more potent as a tubulin polymerization inhibitor.71  
1.4.2 Reported syntheses of CA-1 
The first synthesis of CA-1 was reported together with the isolation and structure elucidation by 
Pettit and co-workers (Scheme 1).67 The benzyl bromide 39 was readily prepared from the 3,4,5-
trimethoxybenzyl alcohol, and further reacted with triphenylphosphine to give quantitative yield of 
the ylide 40. The 2,3-di-tert-butyl-dimethylsilyl ether 41 was prepared from 2,3,4-trihydroxy 
aldehyde (42) by selectively protecting the 2,3-hydroxyl groups as the borate ester and the 4-
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hydroxyl group was selectively methylated with dimethylsulfate. After acidic deprotection of the 
borate ester of 43, disilylation was performed with TBDMSCl. The ylide was prepared with n-BuLi 
in THF and then reacted with the aldehyde 41 to give a mixture of olefins 44 and 45 in a total of 
93% yield in a 1:9 trans/cis mixture. Deprotection of the TBDMS ethers with TBAF produced CA-
1 (19), and further hydrogenation over Pd/C gave CB-1 (28).  
 
 
Scheme 1 First total synthesis of CA-1 and CB-1 by Pettit and co-workers.67 
 
The synthesis was later improved by Orsini and co-workers by employing the benzyl chloride 
phosphonium salt, due to the instability and difficulties with purification of the benzyl bromide 
phosphonium salt (40).76 Pettit and co-workers later improved two of the steps of their first 
synthesis (Scheme 1), compound 43 was synthesized by selective demethylation of 2,3,4-
methoxybenzaldehyde (46) with BCl3. Secondly, the removal of the TBDMS groups of CA-1 (45) 
was performed with 48% HBr (cat.) and potassium fluoride in DMF (Scheme 2).77 
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Scheme 2 Modified CA-1 synthesis reported by Pettit and co-workers. 
 
Recently, the syntheses of 14C-labeled CA-1 and its prodrug have been reported.78,79 
Chemoenzymatic syntheses of CA-1 (19) and CB-1 (28) have been reported in good overall 
yields.80  
Also a one-pot ortho-formylation-Dakin oxidation reaction81 developed in our group, combined 
with a Sonogashira coupling reaction yielded, the diaryl alkyne 47 (Scheme 3). cis-Selective 
hydroboronation or hydrogenation with Pd/C followed by deprotection of the MOM ethers gave 
CA-1 (19) and CB-1 (28) in good yields.82 
 
 
Scheme 3 One-pot ortho-formylation-Dakin oxidation syntheses of CA-1 (19) and CB-1 (28). 
 
1.4.3 Biological activities of CA-1 and its corresponding prodrug  
The isolation and identification of CA-1 (19) as a potent inhibitor of microtubule assembly was 
established in 1987.67 19 binds to or near the colchicine binding site of tubulin and was shown to 
inhibit the binding of [3H]-colchicine to tubulin. In addition, CA-1 (19) has been reported to 
undergo oxidation in vitro to its ortho-quinone derivative that might bind to the thiols groups of 
proteins and possibly nucleic acids (Figure 10).83-86 This secondary mechanism is believed to be 
favourable for its in vivo activities and to be partly responsible for the slightly superior activity of 
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CA-1P over CA-4P.87,88 Moreover, compound 19 can act as a VDA.89 Histologic evidence showed 
that the viable rim of tumour cells surviving single treatment with CA-1P were significantly smaller 
that with CA-4P treatment 72 hours post administration.88 CA-1 (19) has been found cytotoxic 
against numerous cancer cell lines.67,68,74,90,91 Pre-clinical evaluation indicates that CA-1P was 
equally potent as CA-4P at a quarter of the dose. In addition, it induced tumour growth delays and 
regressions were also observed when used as a single agent.87,88,92  
 
 
Figure 10 Structure of combretastatin A-1 (19) and the reaction pathways following oxidation of CA-1. Adopted from 
reference.84 
1.4.4 Analogues of combretastatin A-1 
The combretastatins structure can be described in three parts: A-ring, B-ring and a bridge between 
the two. 
 
Figure 11 The different components of combretastatin A-1 with numbering; A-ring, bridge and B-ring. 
 
Extensive modification of the combretastatin structure has been explored in order to understand the 
structure activity relationships and to discover more potent analogues.93-97 CA-1 (19) has been less 
studied than CA-4 (20) and fewer analogues have been synthesized compared to 20. 
A full review of all of the analogues of combretastatin is more suited for a book than this thesis, 
hence only an overview of the CA-1 (19) analogues will be given. To discriminate between 19 and 
other combretastatin analogues a criterion is that C-2ʹ must be substituted; the bridge must be two 
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atoms; and the A- and B-ring cannot be connected by others means than the bridge. trans-Stilbenes 
will not be discussed as they have been shown to be inactive.74,98,99 Therefore, the modifications 
have been divided into the following groups: A-ring, B-ring and bridge. The two point 
modifications: A/B-ring, bridge/A-ring, bridge/B-ring and finally three point modifications. 
 
A-ring modifications 
Few research groups have attempted to modify the A-ring of the CA-1 (19) structure. Based on the 
SAR data published on CA-4, the 3,4,5-trimethoxyphenyl (TMP) moiety should be conserved as 
altering the substitution pattern has detrimental effect.68,100-102 Never the less some compounds have 
found their way through the synthetic pipeline (Figure 12). 
 
 
Figure 12 A-ring modified CA-1 analogues. 
 
Stilstatin 1 (53) is a naturally isolated compound and had reduced growth inhibition of the L1210 
cell line compared to CA-1 (19). Inhibition of tubulin polymerization and [3H]colchicine binding 
activity was retained compared 19.68 Stilstatin 2 (54) was later synthesized by the same group, both 
compounds were cytotoxic evaluated and found less active than 19.98  
 
Bridge modifications 
 
Figure 13 Bridge modified CA-1 analogues. 
 
The diols 55S and 55R (Figure 13) were significantly less potent tubulin polymerization inhibitors 
than the parent compound CA-1 (19).91 The dioxolane 56S was a highly potent inhibitor of 
microtubule assembly (IC50 = 0.59 µM), twice as potent as 19, and inhibited the growth of P388 cell 
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line with an ED50 ~1.5 µg/mL. The enantiomer 56R inhibited microtubule assembly at a tenfold 
concentration of CA-1.103 Compound 57 had low cytotoxicity compared to the analogues evaluated 
by the authors.104 
 
B-ring modifications 
Modifications on the B-ring of CA-1 have been investigated extensively in comparison to the A-
ring.68,76,85,105-107 The dihydroxyl groups have been replaced by nitro, amine, fluoro, O-acetyl, O-
glycosides and methoxy groups (Figure 14). The difluoro substituted compound 58 increases cell 
growth inhibition 16-fold compared to CA-1in the K562 cell line.107 The diamine analogue 59 
inhibits microtubule assembly with an IC50 value comparable to CA-1. Pleasantly it surpassed CA-1 
with 10-100 fold higher cytotoxicity against six cancer cell lines. The authors stated that 59 was 
capable of forming an ortho-diimine (60) analogous to ortho-quinone of CA-1 (19) without 
providing data for this mechanism.105 
 
 
Figure 14 B-ring analogues of CA-1 
 
The acetylated compound 61 was cytotoxic in the L1210 cell line (IC50 = 0.06 µM) but inhibition of 
tubulin polymerization and [3H]colchicine binding were both significantly lower than CA-1 (19).68 
In general, the compounds 62 and 63 were significantly less cytotoxic than CA-4 (20); both were 
active inhibitors of microtubule assembly, but less active than 19.76,108  
Compound 64 was equally good tubulin inhibitor as CA-1 (19), but lacked cytotoxic activity. 
Compound 65 had good tubulin inhibition and cytotoxicity in the cell lines tested.106 Nitro and 
amine derivatives 66 and 67 were inactive as tubulin inhibitors and as cytotoxic agents.106 
Phenazines 68 and 69 were found to significantly inhibit the growth of P388 cell line with a ED50 ~ 
0.2 µg/mL.85 
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Combinations of A-ring and B-ring modifications 
 
Figure 15 Analogues where the A- and B-rings are modified 
 
The dibromide 70 (Figure 15) showed some activity in the ZR-75-1 breast cancer cell line, about 
one fifteenth as active as CA-4 (20). However, 19 was not evaluated, neither was the iodo analogue 
71.109 The CA-1 analogue 72 was a weak inhibitor of the L1210 cell line and tubulin 
polymerization.68 
 
Combinations of bridge and A-ring modifications 
 
Figure 16 Bridge and B-ring modified CA-1analogues. 
 
The saturated bridge analogue 73 (Figure 16) inhibited tubulin polymerization at twice the 
concentration of CA-1 (19), but was not able to inhibit [3H]colchicine binding to tubulin. 73 
inhibited  growth in the L1210 cell line (IC50 = 8 µM) one tenth the cytotoxic activity of 19.68 The 
tricyclic compound 74 exhibited cytotoxic activity against the cell lines tested, but was less active 
compared to CA-1. Compounds 74 and 75 were inactive as tubulin inhibitors. While compound 76 
was not cytotoxic against the cell line tested, but inhibited microtubule polymerization at one fourth 
of the concentration of CA-1.110  
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Combination of bridge and B-ring, and the three point modified CA-1 analogues 
 
 
Figure 17 Bridge and B-ring modified CA-1analogues. Three point modified CA-1 analogue 
 
The dihydro stilbene 77, compound 78 and 79 (Figure 17) were inactive in the assays tested.68,99,104 
-Lactam analogue 80, with two TMP moieties, was significantly less cytotoxic compared to CA-4 
(20) in the MCF-7 and MDA-MB-231 cell lines.111 The indazole based analogues 81-83 were 
slightly more cytotoxic compared to 19 in the H460 cell line. Further evaluation showed that they 
were all cytotoxic towards PC3, HeLa and HT29 cancer cells as well.112 Only 82 inhibited tubulin 
polymerization in vitro with a similar IC50 value as 20. 
1.4.5 Summary of structure activity relationship for CA-1 analogues 
 
 
Figure 18 Summary of structure activity relationship for CA-1 analogues. 
 
From the SAR reviewed certain trends are notable. The A-ring and the three methoxy groups should 
not be substituted for other groups. The cis configuration of the bridge is essential, but can be 
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exchanged with a dioxolane ring. However, the stereochemistry was important. The 4’-methoxy 
group is important for activity, but the hydroxyl groups can be substituted for amino groups or 
fluorine atoms with improved cytotoxic activity. These SAR trends are similar to what has been 
reported for CA-4.93,113 
1.5 2-Methoxyestradiol 
1.5.1 Introduction 
The discovery of sex-hormones and their biological activities have played an important part in drug 
discovery, and both agonists and antagonists of sex-hormones are used in drug therapy.114 2-
Methoxyestradiol (Figure 19, 2ME2, 85) was believed to be an inactive metabolite of estradiol, 
until the tubulin polymerization inhibition was reported in 1989. The anti-angiogenetic activity was 
first reported five years later.115-118  
 
 
Figure 19 Estradiol, 2-Methoxyestradiol and two analogues, ENMD-1198 and STX140, which are currently in clinical 
trials. 
 
2ME2 has been established as a cytotoxic compound with several modes of action, and has shown 
promising preclinical results as an anti-cancer agent. Several clinical trials in various forms of 
cancer have been conducted.119 Furthermore, compounds 86 and 87, developed from 2ME2, have 
advanced to clinical trials (Figure 19).120 
1.5.2 Syntheses of 2-methoxyestradiol 
An efficient synthesis of 2ME2 (85) has been long sought for since the discovery of its biological 
activities. In 1958 Jack Fishman (Figure 20, path a) reported the first synthesis of 85 from estradiol 
(84). 
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Figure 20 Synthesis of 2ME2 from estradiol with the use of direct hydroxylation as the key step. PG = protection 
group.121-123  
 
With the phenol group protected with 2-chloro-5-nitrobenzophenone and the 17-hydroxyl acetate 
the aromatic ring was ortho-hydroxylated with hydrogen peroxide under acidic conditions, and was 
subsequently methylated with diazomethane. The yield was not reported for this five step 
synthesis.121 Paaren and co-workers (Figure 20, path b) protected estradiol (84) before 
hydroxylation with trimethylborate. Potassium carbonate and dimethyl sulfate was used to 
methylate the 2-hydroxyl group. The synthesis was complete in four steps and 78% overall yield.122 
Wähälä et al. (Figure 20, path c) hydroxylated the protected estradiol with the use of the superbase 
LIDAKOR, trimethylborate and hydrogen peroxide. The methylation was performed with 
potassium carbonate and methyl iodide. 2ME2 (84) was obtained in 61% yield in three steps from 
estradiol.123  
 
 
Figure 21 Halogenation as the key step for the synthesis of 2ME2.124-127 
 
Total synthesis of 2ME2 has been achieved by using 2-halogenation and methoxylation as the key 
steps. Rao and co-workers (Figure 21, path a) prepared 2ME2 (85) from estradiol (84) by 
halogenation with TBCO. This resulted in a mixture of 2- and 4-brominated isomers with the 2-
isomer as the minor component.124 Methoxylation using sodium methoxide in presence of copper 
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iodide afforded 2ME2 (85). This two step synthesis proceeded in 13% overall yield.124 Numazawa 
et al. (Figure 21, path b) reported the synthesis of 85 from the corresponding 2-iodo compound 
using sodium methoxide and copper chloride. This one step procedure afforded 2ME2 in 95% 
yield.125 Zhao and co-workers (Figure 21, path c) used NBS in chloroform to halogenate estradiol 
resulting in an almost 1:1 mixture of 2- and 4-brominated estradiol. The methoxylation reaction was 
performed using sodium methoxide and copper iodide in the presence of benzo-15-crown-5. This 
two step synthesis proceeded in 30% overall yield.126 Xiang and co-workers (Figure 21, path d) 
performed the halogenation on 3-O-benzyl-protected estradiol using bromine in dichloromethane, 
the bromination then occurred regioselectively at the 2-postion. The methoxylation was also in this 
case copper-mediated and the authors used ethyl acetate (60 mol%) as a co-catalyst. Removal of the 
benzyl group afforded 85 in four steps and 61% overall yield.127 
 
 
Figure 22 Total synthesis using the 2-formylation, oxidation and methylation as the key steps.128-130 
 
Several groups have employed 2-formylation, oxidation and methylation as the key steps for the 
syntheses of 2ME2 (85). Cushman and co-workers (Figure 22, path a) formylated estradiol by 
employing Duff reaction conditions, which yielded a mixture of two isomers with the 2-isomer as 
the major product. The hydroxyl groups were protected using benzyl bromide, followed by a 
Baeyer-Villiger/Dakin oxidation of the formyl group. The 2-hydroxyl group was methylated before 
deprotection to the final compound. 2ME2 was prepared in five steps and 6% overall yield.128 Some 
years later the same group reported a similar, but improved, synthetic pathway changing the 
protection group and formylation chemistry as described by Pert131 and Brueggemeier,132 selectively 
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formylating the 2-position of 3,17-bis(MOM) protected estradiol (Figure 22, path b). Furthermore, 
the authors improved the Baeyer-Villiger oxidation conditions which resulted in a five step 
synthesis with 63% overall yield of 2ME2.129 Leese et al. (Figure 22, path c) devised a synthetic 
pathway from estrone (88). After protection of the ketone and hydroxyl groups as an acetal and a 
MOM ether, respectively, the authors proceeded with formylation, oxidation and methylation as 
described earlier by others. 2ME2 (85) was isolated after dual deprotection and reduction of the 17-
keto group with NaBH4. This seven step synthesis afforded 85 in 58% overall yield.130 
There are procedures for the synthesis of 2ME2 (85) that can not be categorized into either of the 
previously described strategies. Amouri et al. prepared 85 by selective ortho-activation of the 
aromatic ring of estradiol towards nucleophilic attack by the Cp*Ir2+-complex. Sodium methoxide 
reacted explicitly at C-2 of the estradiol- Cp*Ir2+-complex installing the 2-methoxy group. 
Subsequent oxidative decomplexation afforded compound 85 in three steps and 60% overall yield. 
However, the iridium reagent was used in stoichiometric amounts.133 
A second 2ME2 (85) synthesis by Rao and co-workers utilized a 2-acyl group instead of a 2-formyl 
group, synthesized by a zirconium-tetrachloride mediated Fries rearrangement. The previously 
mentioned Baeyer-Villiger oxidation and methylation procedures afforded 2ME2 in 40% overall 
yield and seven steps. The authors used five equivalents of zirconium-tetrachloride for the Fries 
rearrangement.134 
Hou and co-workers used a direct methoxylation procedure involving C-2 lithiation followed by 
reaction with cumyl methyl peroxide, thus preparing 2ME2 in three steps and 70% overall yield. 
Though, cumyl methyl peroxide might be shock sensitive and undesirable to handle in large 
quantities.135 
The synthesis reported by Stoelwinder and Moers in a patent from 2006 differs from the other 
reported syntheses. There have been some concern about estrogenic contaminants in the 2-
methoxyestradiol product; therefore the authors envisioned to build the steroid skeleton by stepwise 
synthesis. The two compounds 89 and 90 are combined to make up the different parts of the steroid 
skeleton. Which after two ring closures (91) and aromatization of ring A, as well as a reduction of 
the ketogroup in the 17 position afforded 2ME2 in seven steps (Figure 23). It was not possible to 
determine the overall yield of the synthesis as they are not reported in the patent. There is a clear 
advantage in avoiding estrogenic contaminants, which can possibly affect the results of biological 
testing.136 
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Figure 23 Outline of total synthesis of 2ME2 from non-estrogenic starting materials. 
 
1.6 Molecular modelling 
Since 1970 computers have been readily available for academic applications and several researchers 
embarked on a mission to make an algorithm that would enable docking of small ligands into 
receptors in silico. The first docking program emerged in 1982 when Kuntz and co-workers 
published a computer aided molecular docking on a minicomputer (PDP 11/70) using the known x-
ray structures of heme docked into myoglobin and other known protein-ligand complexes.137 Today 
more than 60 programs and 30 algorithms are available, but only a limited number of them are 
widely used (AutoDock, DOCK, FlexX, FRED, Glide, GOLD, ICM, QXP/Flo+ and Surflex).138 For 
the most part, generating reasonable ligand orientation is considered to be virtually solved, whereas 
imperfections of scoring functions continue to be a major limiting factor.139-141 With an ever-
increasing number of protein structures being solved by X-ray crystallography, the use of protein-
ligand docking algorithms to assess candidate ligands for a binding site has become commonplace. 
However, the techniques and practice of protein-ligand docking in general, and of structure-based 
virtual screening in particular, are still evolving and significant limitations remain to be 
addressed.142 A second virtual technique for the identification of new drug leads is ligand-based 
approaches, which require much less detailed information. At a minimum, a ligand-based technique 
requires knowledge of only one active molecule. The virtual screen is then conducted by identifying 
molecules that share some similarity or properties with that single active molecule. The best known 
among these techniques is the pharmacophore approach, which attempts to abstract features of an 
active molecule (or shared features among a set of active molecules) that are likely to be important 
in binding to the target receptor.143 
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1.6.1 Tubulin structure and colchicine binding  
 
Figure 24 The pdb entry 1SA1 of -tubulin hetero-dimer in complex with RB3-SLD and podophyllotoxin (POD, 
blue). 
 
The colchicine binding site was finally identified in 2004 by Ravelli and co-workers; a x-ray crystal 
structure of -tubulin hetero-dimer in complex with RB3 protein stathmin-like-domain (RB3-
SLD) and DAMA-colchicine or podophyllotoxin (pdb entry 1SA0 and 1SA1, respectively) (Figure 
24).7 The binding site of colchicine was located at the intradimer interface of -tubulin in a 
lipophilic pocket. 
 
 
Figure 25 (a) Tubulin without (yellow) with bound colchicine (green) superimpose over one another, the root mean 
square deviations of the positions of C atoms in secondary structure elements after superposition is 0.8 Å. (b) 
Colchicine (blue) inhibits the -tubulin hetero dimer from adopting a straight conformation. Adapted from reference.7 
24 
 
 
The colchicine binding site is mostly buried in the intermediate domain of the -subunit, boxed in 
by strands S8 and S9, loop T7 and helices H7 and H8 (Figure 25). Colchicine also interacts with 
loop T5 of the neighbouring -subunit. Microtubule stability requires both longitudinal (between 
tubulin subunit  and ) and lateral interactions (between protofilaments). When colchicine binds to 
tubulin, it acts as a wedge between the  and  tubulin hindering the protofilament to adopt a 
straight conformation. The curved tubulin-colchicine complex cannot establish lateral contacts at 
the newly formed end of the protofilament because the M loop is displaced.7  
Several molecular modelling studies, both ligand-based and structure-based, of colchicine site 
inhibitors have been reported. The structure-based approaches have resulted in the identification of 
several residues and interactions supposedly involved in the binding of inhibitors to the colchicine 
site.8 
1.7 ortho-Formylation of phenols 
1.7.1 History 
Salicylaldehydes are useful intermediates in organic synthesis. This class of compounds are 
accessible in several ways starting from substituted phenols (Figure 26). However, for many of 
these classical reactions, the yields of salicylaldehydes are often only moderate and the lack of 
regioselectivity is problematic. Moreover, the reaction conditions are quite harsh, involve safety 
problems at a large scale, and employ environmentally harmful reagents.144-158  
 
 
Figure 26 Classic formylation reactions of phenols: Lender-Manasse,149,150 Gattermann,151,152,156 Reimer- 
Tiemann,145-147,156,159 Gattermann-Koch,160-162 Vilsmeier-Haack153,156,158 and Duff reaction154-156. 
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The selectivity issue has been partly solved for some of the reactions, for instance the Reimer-
Tiemann yields the salicylaldehyde when H2O/EtOH 9:1 (v/v %) is used as solvent.163 The original 
Gattermann-Koch reaction using carbon monoxide under acidic conditions is incompatible with 
phenols. When hydrogen fluoride and boron trifluoride are used as acids the reaction yields 
primarily 4-hydroxybenzaldehydes.161,162 Salts of chromium, zirconium, titanium and iron were 
shown to successfully ortho-formylate phenols at high temperatures and pressure.164,165 
In 1978 a highly selective method for the ortho-formylation of phenols was published by Casiraghi 
and co-workers, employing ethylmagnesium bromide, hexamethylphosphoramide (HMPA) and 
paraformaldehyde in refluxing benzene.166 The authors obtained 2-hydroxybenzaldehydes as the 
only regioisomer in 50-90% yields from phenols substituted with alkyl, alkoxy or chloride groups. 
The method was later modified by the same group; tin tetrachloride and tributylamine in refluxing 
toluene replaced the former solvent and base system (Scheme 4).167 When phenols substituted with 
ortho-methoxy, nitro, ester or methylketone groups were submitted to either of the reaction 
conditions, no formation of the corresponding aldehydes were observed. Levin et al. and Bu et al. 
both improved the method.168,169 
 
 
 
Scheme 4 Two methods by Casiraghi and co-workers for the ortho-formylation of phenols. 
 
Unfortunately, all these reactions are hampered by one or more of the following disadvantages: the 
use of large amounts of Lewis acids, hazardous reagents, difficult separations of isomers, and 
multistep synthesis. Today, there is a general need for more environmentally benign methods. 
In 1999 Skattebøl and Hofsløkken published a convenient ortho-formylating protocol using 
anhydrous magnesium dichloride, triethylamine and paraformaldehyde in refluxing acetonitrile or 
THF (Scheme 5).170 This base system gives higher yields, fewer by-products, and the use of HMPA 
becomes redundant. The reaction was later improved by Hansen and Skattebøl by reducing the 
number of equivalents of magnesium dichloride, triethylamine, and paraformaldehyde to two, two, 
and three, respectively. Salicylaldehydes are obtained in good to excellent yields, 70-99%, using 
this method. Unfortunately only poor yields were obtained using phenols substituted with electron 
withdrawing groups such as nitrile and nitro, except methyl 4-hydroxybenzoate which was 
formylated with a yield of 88%.171 
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Scheme 5 Preparation of salicylaldehydes by ortho-formylation using the MgCl2/Et3N base system. 
 
Skattebøl and Hofsløkken proposed a reaction mechanism for the ortho-formylation reaction with 
magnesium dichloride which is analogous to that of Casiraghi, when magnesium or tin phenoxides 
are employed.166,167,170 The phenoxymagnesium salt (A) coordinates formaldehyde for an 
electrophilic aromatic substitution. After aromatization (B), the salicylalcohol reacts in an 
Oppenauer-Tishchenko type oxidation172,173 with a second equivalent of formaldehyde (C) yielding 
the corresponding salicylaldehyde (Figure 27).  
 
 
Figure 27 Proposed ortho-formylation reaction mechanism. Adapted from reference.170,174 
 
The magnesium dichloride/triethylamine base system has been employed for the preparation of 
useful intermediates and natural products.81,82,171,175-184 
1.7.2 Formylation of resorcinols 
Regioselectivity in formylation of phenols and resorcinols can be a problem as illustrated in Figure 
28. 
 
Figure 28 Substitute patterns on phenol and resorcinols in formylation reactions. 
 
To some extent selectivity between C-2 and C-4 on resorcinol or its mono- or diprotected 
derivatives can be controlled. C-2 is deprotonated if phenyl lithium, n-BuLi or sodium sand is used 
as reagent; subsequently adding DMF or N-methyformanilide yields the C-2 formylated product.185-
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189 While C-4 is formylated when Gattermann/Adams,151,152 Gross,190 Vilsmeier-Haack191-193 or 
reaction methods derived thereof194,195 are employed. Yields are in the range of 45-99%. The 
Reimer-Tiemann reaction with resorcinol or its monomethyl ether gives acceptable yields in 
combination with -cyclodextrin.196 Reaction conditions and yields of reported formylations of 
resorcinols are summarised in Table 1. 
 
Table 1 Reported formylations of resorcinols. 
 
 
Year Author Conditions R1 R2 Yield 92 Yield 93 
1898 Gattermann, L.151 HCN, AlCl3, Benzene H H 99% - 
  HCN, AlCl3, Benzene Me H 80% - 
1923 Adams, R.152 Zn(CN)2, HCl, Et2O H H 95% - 
1940 Wittig, G.185 1) PhLi, Et2O 2) N-methyformanilide Me Me - 55% 
1952 Sommers, A. H.191 POCl3, N-methyformanilide,  <34 °C Me Me 85% - 
1955 Lambooy, J.P.192 POCl3, N-methyformanilide,  100 °C Me Me 72% - 
  POCl3, DMF, 100 °C Me Me 68% - 
1963 Gross, H.190 Cl2CHOMe or HC(OEt)3, AlCl3, PhNO2 
H H 68% - 
1979 Narasimhan, N. S.186 1) n-BuLi, Et2O, rt 2) DMF MOM Me - 90% 
1993 Heaney, H.194 P2O3Cl4, DMF, 20 °C H H 88% - 
  P2O3Cl4, DMF, 100 °C Me Me 99% - 
1996 Mendelson, W. L.193 POCl3, DMF, ACN, -14 °C H H 70-75% - 
  (COCl)2, DMF, ACN, -14 °C H H 66-70% - 
1997 O’Brien, P.187 1) n-BuLi, TMEDA, Et2O, 0 °C 2) DMF, rt 
Benzyl 
derivatives 
Benzyl 
derivatives  - 38-75% 
1997 Zacharie, B.188 1) n-BuLi, Et2O, 0 °C 2) DMF THP Me - 76% 
  1) n-BuLi, Et2O, 0 °C 2) DMF THP MOM 4% 62% 
2001 Bagno, A.  Kantlehner, W.195 
AlCl3, tris(diformylamino) 
methane, DCE, -15 °C Me Me 45% - 
2001 Divakar, S.196 KOH, CHCl3, -cyclodextrin, H2O, 60 °C  
H H 70% - (16%)a 
  KOH, CHCl3, -cyclodextrin, H2O, 60 °C 
H Me 44% - (56%)a 
2002 Wagner, A.189 Na sand, C8H17Cl, DMF,  toluene, rt Me Me - 52% 
aYield of dialdehydes 
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1.7.3 Formylation of estradiol 
Many of the previously mentioned formylation reaction methods have been applied to estradiol 
(84). Reaction conditions and yields of reported formylations of estradiol are summarised in Table 
2. In 1966 the company Organon N. V. filed a patent describing the formylation of estradiol (84) by 
the Reimer-Tiemann reaction. Several research groups have tried to repeat the reaction but only 
with limited success.131,197  
 
Table 2 Reported ortho-formylation of estradiol. 
 
 
Year Author Conditions R1 R2 Yield 94 Yield 95 
1966 Organon N. V.198 1.5 N NaOH, EtOH (69 %), CHCl3, 70 °C 
H H -a -a 
1988 Rugang, X.199 EtMgBr, HMPA, (CH2O)n, Benzene, 80 °C H H 
25% 
(21%)b - 
1989 Ridley, D. D.131 1) s-BuLi, DMF, THF, -78 °C 2) 6M HCl, THF MOM MOM 75% - 
1991 Kourounakis, P. N.197 
1) EtMgBr, HMPA, (CH2O)n, 
    Benzene, 80 °C 
2) 20% NaOH, MeOH 
H H 68% (27%)b - 
1994/5 Cushman, M.128,200 HMT, CF3COOH,  H H 25% 13% 
1995 El-Tombary, A. A.201 
1) TMDM, (CH2O)n, benzene,  
    EtOH,  
2) HMT, AcOH, 65 °C 
H H 36% - 
1996/ 
2001 Brueggemeier, R. W.
132,202 1) s-BuLi, DMF, THF, -78 °C 2) 6M HCl, THF MOM MOM 84%  
1999 Meltola, N.203 EtMgBr, (CH2O)n, (Et)3PO4, Et2O/Toluene, 80 °C 
H H 50% 12% 
2003 Peters, R. H.204 HMT, CF3COOH, 100 °C H H 13% 4% 
  
1) EtMgBr, HMPA, (CH2O)n, 
Benzene, 80 °C 
2) 20% NaOH, MeOH 
H H 94% - 
aNot reported 
bYield of 17-formate (96) 
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By using a heteroatom facilitated ortho-lithiation process and DMF, Ridley and co-workers were 
able to regioselectively formylate the 2-position of 3,17-bis(methoxymethoxy) estradiol.131 The 
groups of Peters and Cushman have formylated estradiol under Duff reaction conditions (HMT, 
acidic cond.), but a mixture of the 2- and 4-regioisomeres was obtained. Only small amounts of 2-
formylestradiol (94) was isolated using this method.128,200,204 Rugang and co-workers ortho-
formylated several estrogens using Casiraghi conditions (EtMgBr, HMPA and paraformaldehyde), 
and reported yields of 25% for 2-formyl estradiol (94) and a 21% yield of the corresponding 17-
formate (96, Figure 29).199 Meltola and co-workers obtained 94 and 95 in a 62% combined yield 
using triethyl phosphate instead of HMPA with the Casiraghi conditions.203 Peters and Kourounakis 
both discarded their earlier formylation attempts with the Duff conditions to the advantage of the 
Casiraghi method. Both groups obtained 2-formyl estradiol (94) in a combined yield of 94% after 
hydrolysis of the corresponding formate ester.197,204  
 
A side reaction that occurs with the Casiraghi method is the trans esterification of the 17-hydroxyl 
group with methyl formate (97) (Figure 29). Methyl formate is most likely a byproduct due to a 
Tishchenko type reaction.172,174 Kourounakis and Peters reported this side reaction, and unlike 
Rugang et al., they hydrolysed the 17-formate of 2-formyl estradiol (96) to the desired compound 
94.197,199,204 
 
 
 
Figure 29 The Tishchenko reaction mechanism and the trans esterification of 94 with methyl formate. 
 
An indirect route to 2-formylestradiol (94) is by aromatization of 2-hydroxymethylene-19-
nortestosterone (98) with DDQ in dioxane (Figure 30).205,206 This method was also applied to 
compound 99 for the synthesis of the corresponding 2-formylestrogen (100) (Figure 30).207 
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Figure 30 Synthesis of 2-formyl estradiol and 17-ethynyl derivative by aromatization.205,206 
 
1.7.4 Formylation of estrone 
As with estradiol, several research groups have attempted the formylation of estrone. The reported 
syntheses are summarized in Table 3. The yields are only acceptable at best.  
 
Table 3 Reported ortho-formylations of estrone and one estrone derivative. 
 
 
Year Author Conditions R1 Yield 101 Yield 102 
1966 Organon N. V.198 1.5 N NaOH, EtOH (69 %), CHCl3, 70 °C 
H -a -a 
1988 Rugang, X.199 EtMgBr, HMPA, (CH2O)n, Benzene, 80 °C H 19%  - 
1989 Ridley, D. D.131 1.5 N NaOH, EtOH (95 %), CHCl3, BnN(Et)3Cl,  
H 2% 16% 
2004 Taylor, S. D.208 MgCl2, Bu3N, (CH2O)n, ACN, sealed tube,  H 52% 4%
b 
2007 Taylor, S. D.209 
1) MgCl2, Et3N, (CH2O)n, 
THF, 40 °C 
2) AlCl3, MeNO2/DCM, rt 
t-Bu - 58% 
aNot reported 
bThe yield was calculated from the reported ratio (14:1) and yield. 
 
Potter and co-workers managed to formylate estrone in good yields by first protecting the 17-
ketogroup with ethylenglycol and thereafter the phenol as MOM ether to give intermediate 103. 
Formylation by ortho-lithiation and DMF yielded protected 2-formyl estrone 104 (Scheme 6).130 
Rugang and co-workers also employed the Casiraghi conditions to 17-ethynyl estradiol (99) and 
the acetal of estrone successfully, obtaining 57-78% and 62% yields of the corresponding 2-formyl 
derivatives, respectively.199,210 
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Scheme 6 Formylation of protected estrone.  
 
Only one group has reported the synthesis of 2-formyl estriol in very poor yields.131 
1.8 1,2,3-Triazoles 
1,2,3-Triazoles are an important class of heterocycles readily available from the 1,3-dipolar 
cycloaddition reactions of organic azides and alkynes.211 They are interesting from a medicinal 
point of view because of their physical and chemical properties. The triazole ring is aromatic 
displaying a strong dipole moment (~5 D), allowing the N-2 and N-3 atoms to participate in 
hydrogen bond formation, dipole-dipole and π stacking interactions. Furthermore, they are stabile to 
acidic or basic hydrolysis as well as sever reductive and oxidative conditions.212 There are 
numerous reported synthetic procedures of 1,2,3-triazoles in the literature.213 
1.8.1 The Huisgen 1,3-dipolar cycloaddition reaction 
1,4- and 1,5-disubstituted 1,2,3-triazoles can be synthesized using the Huisgen cycloaddition 
reaction, which is a 1,3-dipolar cycloaddition reaction, between an azide and an internal or terminal 
alkyne.214 This reaction yields mixtures of 1,4- and 1,5-regioisomers, and it generally requires 
heating and long reaction times. The reaction is thermodynamically favoured due to the high 
potential-energy content of the reactants, but high kinetic energy barriers render the reaction slow at 
room temperature. The reaction forms usually a 1:1 mixture of 1,4- and 1,5-disubstituted 1,2,3-
triazoles. Computational investigation of the activation barriers for the concerted reaction indicated 
that the barriers were quite similar for the formation two regioisomers.215,216 
 
Figure 31 Proposed mechanism for the 1,3-dipolar cycloaddition between an azide and an alkyne.214 
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1.8.2 Selective synthesis of 1,4-disubstituted-1,2,3-triazoles 
In 2002 two independent groups published procedures where copper(I) salts accelerate the Huisgen 
cycloaddition reaction by seven to eight orders of magnitude compared to the thermal 
cycloaddition.216-218 This copper catalysed azide-alkyne cycloaddition (CuAAC) is selective for the 
synthesis of 1,4-regioisomer. The reaction can take place at room temperature or with slightly 
heating in various solvents.218 Due to the extraordinary stability of alkynes and azides towards 
water and oxygen, protection from these elements is superfluous. In fact, many reactions proceed 
readily in water and it is therefore often the solvent of choice, with no organic co-solvent, as the 
reactants not necessarily need to be dissolved for the reaction to proceed. In addition, they tolerate a 
wide variety of functional groups and reaction conditions. Several groups have investigated the 
reaction mechanism.215,216,218-220  
  
1.8.3 Selective synthesis of 1,5-disubstituted-1,2,3-triazoles 
As a complimentary synthesis to the CuAAC reaction, ruthenium catalysts have been employed for 
alkyne-azide cycloaddition to the 1,5-disubstituted 1,2,3-triazoles. The reaction is not as versatile as 
the CuAAC reaction, limited by incompatibility with protic solvents and that heating or microwave 
irradiation is needed. Internal alkynes react readily to trisubstituted triazoles, unlike the CuAAC 
reaction, which requires a terminal alkyne.221-224 
Recently, a transition metal free catalytic synthesis of 1,5-diaryl-1,2,3-triazoles was published, its 
application has yet to be investigated by the scientific community.225 
Another option for the selective synthesis of 1,5-disubstituted 1,2,3-triazoles is the reaction between 
magnesium acetylides and azides. This method was investigated by Akimova et al. in the 1960s and 
they reported poor to moderate yields which might have put others off from using the method.226,227 
The method was revitalized when Krasiński and co-workers tested the reported synthesis from 
Akimovas paper and discovered that they obtained good to excellent yields which in many cases did 
not require further purification by chromatography.228 Aliphatic acetylides are less reactive than the 
corresponding aryl acetylides. Electron-poor azides react much faster than the electron-rich azides. 
Byproducts are often observed when employing long reaction times without strict exclusion of 
oxygen, resulting in oxidative coupling reactions. The 4-halomagnesiotriazole intermediates can be 
trapped with electrophiles other than protons, resulting in a regioselective formation of 1,4,5-
trisubstituted 1,2,3-triazoles. 
33 
 
1.9 Aim of Study 
As previously mentioned, there is a great need for developing new anti-cancer drugs. Today, organic 
chemists should apply more environmentally benign methods for the synthesis of bioactive 
compounds, such as anti-cancer agents. Compared to the many classical formylation methods, such 
as the Reimer-Tiemann, Vilsmeier-Haack, Duff, Gattermann-Koch and Casiraghi, the Skattebøl 
ortho-formylation reaction offers many advantageous. The aims of this thesis were to apply this 
method for the synthesis of: 
 
i. Novel PAC-1 molecules.  
ii. 1,2,3-Triazole analogues of combretastatins A-1.  
iii. The anti-cancer agent 2-methoxyestradiol.  
 
In addition, most of the compounds prepared within these aims, have been subjected to biological 
evaluations as potential new anti-cancer agents. 
 
In addition, we wanted to: 
 
iv. Investigate the regioselectivity of the Skattebøl ortho-formylation reaction for 
oxygenated phenols. 
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2 Results and Discussion 
However beautiful the strategy, you should occasionally look at 
the results. 
Sir Winston Churchill  
 
The papers (see Appendix) and additional results are summarized and discussed in the following 
sections. Papers I-IV are summarized in section 2.1-2.4, respectively and in section 2.5 the 
unpublished molecular modelling results are discussed.   
2.1 Synthesis and biological evaluation of PAC-1 analogues 
2.1.1 Introduction 
Procaspase activating compound 1 (PAC-1, 12), was introduced as a direct activator of pCasp-3 and 
suggested as a therapeutic agent against cancer. The initial biological and biochemical results 
implied that the allyl group and the proton donating effect of the molecule were responsible for the 
activity. Hence, we set forth to synthesize novel derivatives of 12 from products of the ortho-
formylation of phenols. In 2009 it was discovered that the activation of pCasp-3 by PAC-1 (12) was 
zinc chelation dependent. Since zinc is important for many enzymes, among others enzymes 
involved in the cell cycle, there is a necessity to clarify the exact mechanisms of action. Therefore, 
we have investigated the effect of PAC-1 in a non-dividing cell type: cultured cerebellar granule 
neurons from chicken in addition to several cancer cell lines.  
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2.1.2 Synthesis and biological activities of PAC-1 derivatives 
Salicylaldehydes 105-116 were obtained by the previously described ortho-formylation reaction 
(Scheme 7).  
 
Scheme 7 ortho-Formylation of phenols. 
 
Synthesis of hydrazide 120 was achieved with the same synthetic route as Hergenrother et al. and in 
comparable yields (Scheme 8).38 The hydrazide 120 was then condensed with salicylaldehydes to 
form the PAC-1 derivatives. In total, 16 PAC-1 derivatives were synthesized with overall yield 
between 23-67%. 
 
 
Scheme 8 Synthesis of PAC-1 derivatives. 
 
The derivatives synthesized were evaluated against seven cancer cell lines (MDA-MB231; SK-BR-
3; T47D; breast cancer cell lines, SKOV; OVCAR3; ovarian cancer cell lines, WM35; WM239; 
melanoma cancer cell lines) and cell proliferation was measured by [3H]thymidine incorporation 
(Table 4).229 According to Hergenrother and co-workers the IC50 values were related to the pCasp-3 
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concentration in each cell, therefore the pCasp-3 concentrations in eight cancer cell lines were 
investigated with western blot (Figure 32). The concentration of pCasp-3 in the melanoma cell lines 
were significantly higher compared to the other cell lines. The western blot showed that MDA-
MB231, SKBR-3, SKOV and OVCAR8 had low concentration of pCasp-3. The PC12 and T46D 
cells had medium concentrations of pCasp-3. To one well three times the amount of the T47D cell 
protein extracts was added to confirm a quantity dependent signal in the western-blot procedure.  
 
 
    PC12      MDA-MB231  SKBR-3   SKOV   OVCAR8      WM35    WM239      T47D      T47D (x3) 
Figure 32 Western blot shows expression level of pCasp-3 (37 kDa) in eight cancer cell lines. To the two wells of T47D 
were added 15 µl and 45 µl cell protein extracts, respectively. The primary antibody was anti-caspase-3 (1:750, Cell 
Signalling). The secondary antibody was donkey anti-rabbit-hrp (Pierce). The blot was imaged with Bioimaging System 
(Syngene, Synoptics Ltd). 
 
Table 4 Effects on viability of PAC-1 derivatives in seven cancer cell lines. Values are per cent of [3H]thymidine 
incorporation of vehicle treated control at a compound concentration of 5 µM. 
 
       
Compound R1 R2 T47D 
MDA-
MB231 SK-BR-3 SKOV OVCAR8 WM35 WM239 
PAC-1 (12) Allyl H 11% 22% 7% 19% 28% 5% 27% 
121 Ethyl H 13% 8% 17% 11% 19% 1% 1% 
122 Propyl H 13% 16% 4% 27% 28% 3% 1% 
123 i-Propyl H 13% 14% 26% 16% 21% 5% 10% 
124 t-Butyl H 21% 26% 15% 26% 23% 9% 8% 
125 Phenyl H 12% 19% 4% 32% 11% 4% 2% 
126 Cyclopenthyl H 10% 16% 9% 6% 10% 1% 1% 
127 Cyclohexyl H 6% 11% 4% 14% 15% 2% 3% 
128 Benzyl H 6% 14% 2% 13% 11% 1% 1% 
129 Ethoxy H 68% 36% 82% 37% 37% 5% 19% 
130 t-Butyl t-Butyl 9% 10% 8% 2% 12% 1% 0% 
131 Nitro H 85% 102% 136% 96% 79% 66% 78% 
 
 
 
37 kDa 
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Compound R T47D MDA-MB231 SK-BR-3 SKOV OVCAR8 WM35 WM239 
132 
 
55% 73% 59% 22% 39% 1% 10% 
133 
 
91% 94% 87% 94% 86% 106% 85% 
134 
 
34% 21% 29% 46% 47% 40% 43% 
135 
 
70% 37% 67% 22% 23% 8% 18% 
 
In general, compounds 121-130, 132 and 135 were equally or more anti-proliferating than PAC-1 
against the melanoma cell lines WM35 and WM239 (Table 4). The activity was in agreement with 
the amount of pCasp-3 found in the cells. The proliferating activity in the cells lines with highest 
pCasp-3 concentration were most affected by treatment with PAC-1 derivatives. The Hergenrother 
group discovered that the procaspase activating properties of PAC-1 was due to zinc chelation by 
the salicylaldehyde semicarbazone moiety (Section 1.3.3, Figure 5).46,47 The UV-Vis spectra of 
PAC-1 is depicted in Figure 33. There is a clear decrease in absorption at ~280 nm and an increase 
at 410 nm which indicated that Zn2+ influenced the conjugated π-electrons of PAC-1. 
 
Figure 33 PAC-1 chelates zinc. 50 µM PAC-1 treated with increasing concentrations of added ZnSO4. 
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Compound 131 lack of activity may be assign to the electron withdrawing properties or an 
intramolecular hydrogen bond to the phenol by the nitro substituent. In hindsight, it is logical that 
compounds 133 and 134 were less active as the phenolic moieties are alkylated and unavailable for 
zinc chelation. The naphthalene derivative 132 and compounds 129 and 135 were poor proliferating 
inhibitors in the cell lines except the melanoma cell lines. The benzyl 128 and di-t-butyl 130 
derivatives inhibited [3H]thymidine incorporation with at least 86% in all the cell lines, and were 
the most potent anti-proliferating derivatives tested.  
Compounds 128 and 130 were further evaluated for cytotoxic activity in the PC12 cell line. The 
IC50 values of PAC-1 (12), measured by MTT, were not significantly different in PC12 cells 
between 48 or 72 hours. In the PC12 cell line the compounds 12, 128 and 130 showed similar trends 
in activity, but roughly a tenfold difference in activity between the [3H]thymidine and MTT assay 
values was observed (Figure 34). An explanation might be that [3H]thymidine incorporation 
measures the cells proliferating activity and the MTT assay measures cell viability. This indicates 
that PAC-1 and the derivatives were cytostatic at approximately one tenth of the cytotoxic 
concentration. 
 
  
Figure 34 Plot of PC12 cell viability against concentration of compounds PAC-1 (12), 128 and 130. Values are average 
of 6 independent measurements. (a) [3H]Thymidine incorporation, t = 72 h. (b) MTT assay, t = 48 h. 
 
High concentrations of compound 130 was poorly soluble in the PC12 medium, probably as a result 
of its high lipophilic property (cLogP = 5.79). One might speculate how this influences the activity 
in the MTT assay, from the data presented in Figure 34b, 130 was less cytotoxic than 12 and 128. 
Crystal formation was observed in the medium when 100 µM PAC-1 was added. This indicates that 
the concentration could have been lower than estimated.  
Cytotoxic activity of 100 µM PAC-1 or 128 was not inhibited when cells were pretreated with EGF 
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(Figure 35a). When pretreated with NGF slightly more viable cells were observed in the PAC-1 (12) 
treated cells (Figure 35b). The caspase-3 inhibitor Ac-DEVD-cmk (Figure 35c) or pancaspase 
inhibitor Boc-D-fmk (Figure 35d) had little effect on cell death for PC12 cells treated with PAC-1 
(12) or 128, indicating that the contribution of caspases in cell death is minor. These findings have 
been confirmed by others.230,231 In neurones however, Ac-DEVD-cmk protected significantly 
against 12 induced cell death. This indicates that PAC-1 (12) induces cell death by other 
mechanisms in PC12 cells. 
 
   
  
Figure 35 Influence of inhibitors and growth factors on cell viability in combination with 100 µM PAC-1 (12) or 100 
µM compound 128 measured by MTT assay. The concentrations used were EGF 5 ng/ml, NGF 50 ng/ml, Ac-DEVD-
cmk (1 µM) and Boc-D-fmk (10 µM). The experiments were performed as three individual experiments in duplicates. 
 
2.1.3 Conclusions 
By using the ortho-formylation reaction 16 PAC-1 derivatives were synthesized and evaluated for 
anti-proliferating activities against seven cell lines. Most of the derivatives inhibited proliferation 
equally or better than 12 in the melanoma cell lines WM35 and WM239. Analogues 128 and 130 
had comparable activity to PAC-1 in the PC12 cell line measured by [3H]thymidine incorporation or 
MTT assay. The cytotoxicity of PAC-1 and compound 128 in the PC12 cells were not influenced by 
addition of EGF or NGF at the concentration tested. Inhibitors Ac-DEVD-cmk and Boc-D-cmk 
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could not prevent PAC-1 (12) or 128 induced cell death at a compound concentration of 100 µM. 
2.2 ortho-Formylation of oxygenated phenols 
The reported regioselective ortho-formylation reaction of substituted phenols using the MgCl2-Et3N 
base system and paraformaldehyde affords salicylaldehydes in excellent yields.170,171 The 
salicylaldehydes obtained by this method have been employed by us and others for the preparation 
of useful products and intermediates. We wanted to extend this methodology to substituted mono-
protected resorcinols, a structural feature found in many natural products and biologically active 
substances.232-238 As a part of the initial hypothesis that the compound 12 was a proton donor to the 
triaspartic safety catch of pCasp-3, resorcinols aldehydes were thought of as potential building 
blocks for the condensation with the hydrazide 120 evolving into a compound with two available 
protons, hence twice the potential activity (Figure 36).  
 
 
Figure 36 Synthesis of resorcinol analogues of PAC-1. 
 
A second objective was to explore the regioselectivity of the ortho-formylation reaction on mono-
protected resorcinols. ortho-Formylation of resorcinol, catechol, pyrogallol or phloroglucinol with 
the MgCl2/Et3N base system resulted in polymerization. Resorcinols were protected under standard 
procedures and the di- and mono-protected derivatives were separated by chromatography. The 
results are summarized in Table 5 and Table 6. ortho-Formylation of the pivalate 137a and tert-
butylcarbonate 138a protected resorcinols resulted in a mixture of products. The C-6 formylated 
products, 137c and 138c, were the minor component. Though not investigated, the reaction 
conditions could be responsible for hydrolysing the esters/carbonate of compounds 136b-138b, 
resulting in low yields of the mono-protected compound. The TMS and TES mono ethers of 
resorcinol were unstable and did not provide any formylated products. The mono TBDMS ether of 
41 
 
catechol was not either formylated. The di-protected phloroglucinols 154b/c and 155b/c were 
obtained in low yields and the C-2 and C-6 formyl mixtures were inseparable by chromatography. 
Based on 1H-NMR analysis of the product mixture; the ratio of 155b and 155c were approximately 
1:1. The products of the ortho-formylation of TBDMS protected phloroglucinol 156a were formed 
in a 3:1 ratio. 
 
Table 5 Results of ortho-formylation of mono-protected resorcinols. 
 
 
 
Entry Compound R1 R2 X Yield b Yield c 
1 136a H Ac H 20% - 
2 137a H Piv H 39% 2%b 
3 138a H Boc H 30% 2%b 
4 139a H Thexyldimethylsilyl H 88% - 
5 140a H Me H 92% 5% 
6 141a H Bn H 88% - 
7 142a H TBDMS H 80% - 
8 143a H Me Cl 94% - 
9 144a H Bn Cl 85% - 
10 145a H TBDMS Cl 60% - 
11 146a TBDMS H Cl - 73% 
12 147a H Me Br 90% - 
13 148a H TBDMS Br 73% - 
14 149a TBDMS H Br - 85% 
  bBased on 1H-NMR analysis  
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Table 6 Results from ortho-formylation of protected catecholes and phloroglucinols. 
 
 
 
Entry Compound R R1 R2 R3 Yield b Yield c 
1 150a H OH OMe Me 11% - 
2 151a H OH     -OCH2- 97% - 
3 152a OH H     -OCH2- 45% - 
4 153a H OH       -OC(CH3)2- 82% - 
5 154a OH OMe H TBDMS 20% 
6 155a OH OMe H Bn 30% 
7 156a OH OMe H Me 21% 
 
 
 
Scheme 9 The synthesis of compound 159. 
 
To finalize the initial prospect for the ortho-formylation of resorcinols; two PAC-1 derivatives were 
synthesized. The compound 135 was synthesized from 151b and is found in section 2.1.2. 
Desilylation of compound 149c proceeded cleanly with TBAF at 0 °C in THF, and yielded 
compound 158 (70%) (Scheme 9). The product was condensed under standard conditions with 
hydrazide 120 to PAC-1 derivative 159 in 33% yield. 
2.2.1 Conclusions 
In conclusion, we have extended the experimentally simple and regioselective ortho-formylation 
protocol to mono protected resorcinols and methylenedioxy substituted phenols. The formylations 
proceeded with high to excellent yields and regioselectivity. Two of the synthesized aldehydes were 
condensed with hydrazide 120 to form PAC-1 derivatives 135 and 159. 
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2.3 ortho-Formylation of estrogens and synthesis of 2-
methoxyestradiol 
2.3.1 ortho-Formylation of estrogens 
Functionalization of organic compounds is an important chemical formation often necessary for the 
synthesis of analogues. Aldehydes are such functional handles, and they can be added to aromatic 
compounds by several efficient formylation methods (see section 1.7.1).156-159 Estrogens are a class 
of compounds that could benefit from such a functional group addition. A protocol for selective 
ortho-formylation of phenols using benign conditions and reagents was described by Skattebøl and 
Hofsløkken.170,174 An unaddressed issue is the regioselectivity when dealing with meta-substituted 
phenols.  
The A-ring of estrogens could be considered as meta- and para-substituted phenol, an intriguing 
predicament for selectivity of the ortho-formylation reaction. Therefore several commercially 
available and synthesized estrogens were subjected to the reaction conditions. The results are 
summarized in Table 7. The regioisomeric ratio was determined by LC/MS and 1H-NMR analyses. 
All estrogens were formylated in good yields except estriol (163). The acetal 164 was hydrolyzed 
during work up of the reaction mixture and the 2- and 4-formyl estrone, 101 and 102, were found in 
the crude mixture. 
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Table 7 ortho-Formylation of estrogens. 
 
Estrogen R1 R2 R3  
Regioisomeric ratio 
(a:b)a Yield%
b 
84 OH H H  13:1 92 
99 OH CCH H  6:1 86 
160 OH CH2CH3 H  12:1 90 
161 H OH H  13:1 85 
162 OAc H H  8:1 90 
163 OH H OH  n.d.c 15 
88 =O H  9:1 90 
164 OCH2CH2O H  12:1 74d 
a The regioisomeric ratios of the salicylaldehydes were determined by LC/MS analysis.  
b The yields and regioisomeric ratios are based on three experiments. The regioisomeric ratios were constant in all 
experiments. 
c Not determined. 
d A 12:1 regioisomeric mixture of 101 and 102 was also obtained in 14% isolated yield. 
 
Several of the reaction reagents were investigated on estradiol (84). Replacing the solvent with 
DCM, dioxane, toluene, DMF or ACN gave no or poor yields. This was surprising as both ACN and 
DCM have been successfully employed by others in combination with these reagents.170,208 THF 
was, under these conditions, the superior solvent tested for this transformation on 84.  
In the same ortho-formylation reaction conditions with estradiol, triethylamine was exchanged with 
diazabicyclo [5.4.0] undec-7-ene (DBU), 4-dimethylaminopyridine (DMAP), 
diisopropylethylamine (DIPEA), diisopropylamine, piperidine or dimethylethylamine. All liquid 
bases were distilled prior to use and kept over 3 Å molecular sieve. Unfortunately, none of the bases 
were able to fully convert estradiol to 94 and 95. In all reaction mixtures estradiol was found in 
quantities of 25-60%, quantified by 1H-NMR analyses. The regioisomeric ratio varied from 2:1 to 
5:1, all inferior to triethylamine in regards of selectivity towards compound 94. 
Furthermore, divalent inorganic salts were investigated for their influence over the ortho-
formylation regioselectivity and yield. Anhydrous magnesium iodide, magnesium bromide, zinc 
chloride, copper chloride, calcium chloride and non-anhydrous quality of magnesium bromide were 
tested. All the salts are hydroscopic, and the magnesium and zinc salts are even deliquescent. The 
anhydrous zinc and magnesium chloride salts are unobtainable from their hydrates by simple 
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heating as this result in the production of oxychlorides and liberation of hydrochloric acid. The 
anhydrous salt can be prepared in the laboratory, but requires sublimation of the salt by strong 
heating (700 °C) under the corresponding hydrohalogen acid atmosphere.239,240  
Copper chloride and calcium chloride were not reactive under the reaction conditions employed. 
The anhydrous magnesium iodide and the non-anhydrous quality of magnesium bromide were less 
reactive than anhydrous magnesium bromide, both leaving 60% unreacted estradiol while the latter 
left 40% unreacted estradiol, respectively. The regioisomeric ratios (94:95) were in-between 7:1 and 
11:1, none-anhydrous magnesium bromide the least and zinc chloride was the most selective.  
2.3.2 Synthesis of 2-methoxyestradiol 
2-Methoxyestradiol (85) was synthesized one year before it was identified as a natural metabolite in 
1959.121,241  Forty years later the tubulin inhibition properties of 85 were discovered and set forth a 
crusade for an efficient synthesis (see section 1.5).115  It was also discovered to be an inhibitor of 
angiogenesis.116-118  
 
 
Figure 37 Structure of estradiol and 2-methoxyestradiol. 
 
Our approach to the total synthesis of 2ME2 was identical to that of others, except for employing 
the ortho-formylation reaction using MgCl2/Et3N and paraformaldehyde for installing the initial 2-
formyl group (Scheme 10).129 Estradiol (84) was formylated with the described method resulting in 
a 13:1 mixture of 94 and 95 but was also contaminated with ~10% of the 17-formate (96). The 
reaction mixture was hydrolyzed with 2M LiOH in methanol before the 3- and 17-hydroxyl groups 
were protected as bis(MOM) ethers. The two regioisomers were separated by chromatography and 
the 2-fromyl bis(MOM) ether 166 was isolated in 60% yield over the course of three steps. The four 
following steps provided 85 in 36% overall yield.  
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Scheme 10 Synthetic route to 2ME2. 
2.3.3 Conclusions 
In conclusion, the experimentally simple and regioselective ortho-formylation protocol of phenols 
was extended to several estrogens. All but one of the formylations occurred with high to excellent 
yields. In all cases, formation of the 2-isomer was highly preferred. Our studies indicate that the 
ortho-formylation of estradiol was sensitive to variations in base, salt or solvent used. The ortho-
formylation reaction was successfully applied to the total synthesis of 2ME2, which gave the final 
compound in an overall yield of 36%. This synthesis compares favourably to other syntheses 
published, especially with respect to yield and simplicity. 
2.4 Synthesis and biological evaluation of combretastatin A-1 
analogues 
Combretastatin A-1 (19) has attracted interest as a lead compound due to its anti-cancer properties 
(see section 1.4), but received less attention than CA-4 (20). The poor aqueous solubility of CA-1 
was improved by the synthesis of its phosphate prodrug.77 The phosphate prodrug of CA-1 (21) is a 
more potent VDA than CA-4P (22), and is currently in a phase I clinical trial. Potential energy 
surface calculation indicates that CA-1 cis-configuration is favoured.242 The importance of retaining 
a cis-configuration has been confirmed by SAR studies on CA-4 and CA-1. As mentioned, the 
trans-isomers of CA-1 and CA-4 are inactive in biological assays.74,98,99  
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2.4.1 Synthesis of 1,4- and 1,5-disubstituted 1,2,3-triazole analogues of CA-1 
Structure activity relationship studies of CA-1 (19) and CA-4 (20) have shown that a 
3,4,5-trimethoxy substituted A-ring and a 4ʹ-methoxy substituted B-ring separated by a double bond 
with cis-configuration are important for optimal cytotoxic activity. This prompted us to prepare a 
series of cis-restricted analogues of 19 by replacing the olefinic bridge with a 1,5-disubstituted-
1,2,3-triazole. Our aim was to improve the anti-cancer activities and water solubility compared to 
CA-1 (19). The olefinic bridge of 20 has been successfully replaced by 1,5-disubstituted-1,2,3-
triazole in our lab and others.229,243-246  
 
 
Scheme 11 Synthesis of azide 170. 
 
Preparation of azide 170 was achieved from the boronic acid 169 in reaction with copper sulphate 
and sodium azide as previously reported.243 The azide was used without further purification after 
work up.247 
 
 
Scheme 12 Nitration of 4-methoxy-2-nitro-benzealdehyde. Attempted synthesis of 174 by the Colvin rearrangement 
and the Corey-Fuchs reaction method. 
 
For the synthesis of the dinitro compound 173, 4-methoxy-2-nitro-benzealdehyde (171) was treated 
with nitric acid in fuming sulphuric acid (Scheme 12).105 An approximately 1:1 mixture of the 2,3- 
and 2,5-dinitro benzadehydes, 172 and 173, were isolated. Roughly 10% of the aldehydes were 
oxidized to the benzoic acid observed by 1H- and 13C-NMR analyses. The aldehyde and acid had 
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identical retention factor (Rf) on normal phase TLC and were inseparable by chromatography or 
acid/base extraction. The aldehyde/acid mixture was used in the preparation of the alkyne 174. 
Neither the Colvin rearrangement nor the Corey-Fuchs method was able to produce the desired 
alkyne from the aforementioned mixture.248,249 The experiments indicated that the dinitro moiety 
was incompatible with strong base (Scheme 12). Fortunately, the mild and practical method of 
Ohira-Bestmann completed the task.250-252 The aldehyde/acid mixture of 173 was reacted with the 
reagent 175 at 0 °C in the presence of potassium carbonate in methanol to produce the 
corresponding alkyne 174 (Scheme 13). 
 
 
Scheme 13 Syntheses of compounds 174 and 177 with the Ohira-Bestmann reagent. 
 
Ph.D. student Kristin Odlo synthesized 1-ethynyl-2,3-difluoro-4-methoxybenzene (177) in 43% 
yield by the means of the Colvin rearrangement.113 An improved synthesis for 177 was desired and 
the corresponding aldehyde 176 was subjected to the Ohira-Bestmann conditions (Scheme 13). The 
alkyne 177 was analytically pure after work up of the reaction mixture, and was obtained in more 
than 85% yield after chromatography. It should be mentioned that the 2,3-difluoro alkyne 177 was 
volatile and sublimated in vacuum at room temperature.  
 
 
Scheme 14 Synthesis of 1,2,3-triazole CA-1 analogues 178-181. 
49 
 
 
The 1,2,3-triazoles 178 and 179 were synthesised by a thermal Husigen 1,3-dipolar cycloaddition 
(Scheme 14). Azide 170 was reacted with alkyne 174 in refluxing 1:1 (v/v) toluene/water for four 
days. The reaction was monitored by TLC and did not proceed to completion even after two weeks 
of reaction time. The thermal Husigen 1,3-dipolar cycloaddition afforded 1,5- and 1,4-disubstituted 
1,2,3-triazoles, 178 and 179 in high yields and roughly 1:1 mixture. The dinitro compounds were 
synthesized as intermediates to the desired diamine 1,2,3-triazoles 180 and 181. Combretastatin A-1 
and A-4 analogues have in general been equal or more active when substituting hydroxyl groups 
with amines.102,105,229,244,253,254 Siles and co-workers applied zinc dust in acetic acid for the reduction 
of vicinal nitro groups for the synthesis of a diamino analogue of CA-1 (59).  When compound 178 
was submitted to the same reducing conditions, a complex reaction mixture was obtained. 
Reduction with hydrogen (1 atm.) over Pd/C in methanol was not successful. Following the 
protocol of Yoo and co-workers, the nitro groups were reduced with NaBH4 and CuSO4•5H2O in 
methanol, which afforded the compounds 180 and 181. Unfortunately only poor yields were 
obtained.255 
 
 
Scheme 15 CuAAC synthesis of 179. 
 
For a selective synthesis of 1,4-disubstituted 1,2,3-triazole 179, the CuAAC reaction conditions 
were applied to azide 170 and alkyne 174. Initially, the standard conditions with CuSO4•5H2O (0.1 
mol/eqv.) and sodium ascorbate (0.05 mol/eqv.) in water/t-BuOH were employed at room 
temperature. After 24 hours, no formation of the product was observed by TLC analysis. Increasing 
the temperature to 45 °C did not accelerate the formation of the product. Only when adding a total 
of 1 molar equivalent of CuSO4•5H2O and 0.5 molar equivalent of sodium ascorbate, the reaction 
proceeded and 179 was isolated in 67% yield after purification by chromatography. 
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Scheme 16 Synthesis of CA-1 1,5-disubstituted-1,2,3triazole analogues. 
 
The acetal 190 and acetonoide 191 were readily available in our laboratories using the selective 
ortho-formylation reaction of phenols as a key step in their preparation. Phenol 151a was acquired 
from the commercially available aldehyde 182 by a Baeyer-Villiger oxidation.256-258 Alternatively 
pyrogallol 183 was reacted with DMP to give phenol 153a.259 Both phenols were reacted with Et3N, 
MgCl2 and paraformaldehyde to provide the salicylaldehydes 151b and 153b in excellent yields. 
The salicylaldehydes were protected with MOMCl using standard conditions.260,261 Alkynes 186 and 
187 were obtained by the Colvin rearrangement from the protected aldehydes 184 and 185. To 
selectively synthesize the 1,5-disubstituted 1,2,3-triazoles the alkynes 186 and 187 were treated 
with ethylmagnesium bromide to produce the magnesium acetylides, which were reacted with the 
3,4,5-trimethoxy azide 170. The MOM ethers were removed in refluxing 1:1 THF/3M HCl 
affording the 1,5-disubstituted 1,2,3-triazole CA-1 analogues 190 and 191 in 54% and 65% yield, 
respectively.  
2.4.2 Biological activities 
The CA-1 analogues in Figure 38 were evaluated for their cytotoxic activity in four cancer cell lines 
(MCF-7; breast cancer cell line, H460; lung cancer cell line, HT-29; colorectal cancer cell line and 
CEM; leukemia cell line), tubulin polymerization inhibition and anti-angiogenetic activity. The 
results are summarized in Table 8. 
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Figure 38 Combretastatin analogues evaluated in four cancer cell lines and their anti-angiogenetic and tubulin 
inhibitory activities. 
 
Compound 192 had half the activity compared to CA-1 of tubulin polymerization inhibition. The 
diamino analogue 180 was less cytotoxic to the cancer cell lines tested, but exhibited improved anti-
angiogenetic activity compared to 19. It showed similar tubulin polymerization inhibition activity 
compared to CA-1 and CA-4 analogue 193.229 Compound 190 was cytotoxic to H460 and HT-29 
cell lines and had similar anti-angiogenetic activity as CA-1 (19). From a practical point of view, 
compound 194 was considered inactive in the cell lines tested. The dinitro compound 178 was 
cytotoxic in all the cancer cell lines but also in the non-cancerous fibroblast cell line. Noteworthy, 
178 was the only compound tested that was cytotoxic in the CEM cancer cell line. The 1,4-
disubstituted 1,2,3-triazole analogues 179 and 181 had some activity against the H460 cell line. 
  
Table 8 Cytotoxicity, inhibition of angiogenesis and inhibition of tubulin of the 1,2,3-triazole CA-1 analogues.  
Compound 
MCF-7  
cell assay 
IC50 (µM)a  
H460  
cell assay 
IC50 (µM)a 
HT-29 
 cell assay 
IC50 (µM)a 
CEM cell 
assay 
IC50 (µM)a 
Fibroblast 
cell assay 
IC50 (µM)a 
Inhibition of 
angiogenesis 
(µM)a 
Tubulin 
inhibition 
(µM)b 
19 75.9 1.83 0.87 >100 >100 3.2 3.50c 
178 6.14 0.73 12.0 26.0 31.5 4.39 n.d.d 
179 >100 18.2 >100 >100 >100 >10 n.d.d 
180 38.8 17.3 17.3 >100 >100 0.25 5.20 
181 >100 29.8 >100 >100 >100 >10 n.d.d 
190 >100 7.44 8.80 >100 >100 3.44 n.d.d 
191 46.3 16.8 >100 >100 >100 >10 n.d.d 
192 - - - - - - 7.00c 
193 - - - - - - 4.80c 
aResults of three experiments. 
bResults of two experiments. 
cAdapted from K. Odlos thesis or from Hansen and co-workers.113,229  
dn.d. = not determined 
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2.4.3 Conclusions 
In summary, six 1,2,3-triazole analogues of CA-1 were synthesized and evaluated for biological 
activities. The 1,5-disubstiuted 1,2,3-triazole analogue 180 of CA-1 exhibited cytotoxic effects 
against several cancer cell lines in the low micromolar range. In addition, it exhibited modest 
inhibition of tubulin assembly and effects with IC50-values in the comparable to CA-1 and 
compound 193.  
2.5 Molecular modelling studies 
A set of 17 compounds, consisting of CA-1 (19), CA-4 (20), 1,4- and 1,5-disubstituted 1,2,3-
triazole CA-1 analogues (Figure 39), were docked into the colchicine binding site of tubulin. The 
molecules were synthesized in our labs except for compounds 194 and 195 which were virtual 
compounds. Post publication of the x-ray structure of the DAMA-colchicine-tubulin complex, there 
is a general consensus that TMP containing compounds must have the TMP superimposed with that 
of colchicine when docked into the tubulin structure.8 
 
 
Figure 39 Combretastatin analogues; virtual and synthesized for in silico docking. 
 
2.5.1 Coordinate scan 
By calculation (coordinate scan) the inversion barrier of the A- and B-ring of the 1,5-disubstituted 
1,2,3-triazole analogues, 178, 180, 190-193, 196, 197, CA-1 and CA-4 were investigated and 
evaluated to determine if there was reason to suspect that the compounds are mixtures of 
enantiomers (Figure 40). Ahn and co-workers investigated the impact of different torsional angels 
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to the biological activity of their analogues (57, 78 and 79, Section 1.4.4, Figure 13 and Figure 
17).104 The authors observed that “an optical torsional angles” might be necessary for biological 
activity. The tubulin inhibition activity difference observed between enantiomers 56R and 56S 
(Section 1.4.4, Figure 13) indicate that the position of the A- and B-ring in the plane of the 
dioxolane ring affects activity.   
 
Figure 40 Chiral or mirror representation of difluoro analogue 196. The aromatic A- and B-rings are positioned over or 
under the plane of the triazole ring. Element colour; Carbon (grey), hydrogen (white), oxygen (red), nitrogen (blue) and 
fluoro (green). 
 
 
Figure 41 The dihedral angles 1 and 2 were each changed with 5° increments. 
 
The two dihedral angles between the triazole and the A- (1) and B-ring (2) were systematically 
changed and the conformational energy calculated after energy minimization was performed 
(Figure 41). The energy plot for compound 178 is depicted in Figure 42, similar plots were obtained 
for the other compounds. The change in conformation occurs when the A-ring is 90 degrees on the 
triazole and 2 changes from negative to positive when the C-2ʹ and C-3ʹ substituents are directed 
away from the TMP (Figure 43). 
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Figure 42 Energy (kcal/mol) plot of compound 178 when shifting the 1 and 2 angles. (a) The total relative energy 
surface. (b) Extraction of plot a. The inversion of conformation takes place between 1 = 90° and 2 = 0°.  
 
For CA-4 (20) and compounds 190-192, 196 and 197 the inversion barriers value were less than 5 
kcal/mol (appendix Table 9), which is a low energy barrier and indicates that the two enantiomers 
may interconvert and equilibrium between the two are established quickly at room temperature. In 
the case of CA-1 (19) and compounds 178, 180, 194 and 195 the energy barriers exceeded 5 
kcal/mol and were 6.4, 9.2, 9.7, 8.5 and 8.9 kcal/mol, respectively. This indicates that 1,5-
disubstituted 1,2,3-triazoles synthesized with a large C-2ʹ substitute are formed as enantiomeric 
mixtures. 
 
Figure 43 Angels of inversion of compound 196, 1 = 90° and 2 = 0°. 
 
The different enantiomers (1 and 2 or -1 and -2) were submitted for in silico docking into the 
tubulin structure. The results were comparable for the two enantiomers. However, the docking 
program stochastically selects conformations of the molecule, thus ignoring the conformation of the 
input structure. 
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2.5.2 Comparison of the 1SA0 and 1SA1 tubulin structure 
There are two tubulin-ligand complexes described in the literature, the ligands are DAMA-
colchicine and podophyllotoxin, pdb entry code 1SA0 and 1SA1, respectively. Besides the different 
ligands, the two protein structures have been solved to different resolutions (3.58 Å vs. 4.20 Å). A 
closer investigation of the binding pocket revealed that the backbones of the two proteins are 
aligned to within 5 Å from the ligands except for residues Thr 179 and Ser 178, which are part of 
the T5 loop of -tubulin. For these two residues the back bone and side chains do not match, the 
side chains are pointing in opposite directions (Figure 44a). The side chain of residue Lys 254 in 
the 1SA1 structure is not defined in the x-ray crystal structure; the protein preparation wizard 
simulated a replacement equal to that of 1SA0. With the Sitemap function of the Schrödinger 
package the area around the ligand was investigated. The limits were defined as 3 Å from the ligand 
and 1 Å radius around the probes. Analysis of the receptor pocket illustrate that the 1SA0 pocket 
has a smaller hydrophobic area than the 1SA1 pocket (332.1 Å2 vs. 478.9 Å2), while the receptor 
sites total surface areas are virtually the same (1567.3 Å2 (1SA0) vs. 1531.9 Å2 (1SA1)). This 
indicates that 1SA1 more easily can accommodate ligands, as a major driving force for docking are 
hydrophobic interactions. Originating from the Thr 179 and Ser 178 side chains, a hydrophilic 
area in the 1SA0 structure was oriented towards the mercapto acetyl of DAMA-colchicine (Figure 
44b). The corresponding polar surface in the 1SA1 structure is oriented differently, as expected 
looking at the amino acid residues.  
 
 
Figure 44 (a)1SA0 tubulin-DAMA-colchicine complex (gray) and the 1SA1 tubulin-podophyllotoxin complex (black). 
The side chains of the residues Thr 179 and Ser 178 are not superimposed in the two protein structures. (b) The polar 
surface of Thr 179 and Ser 178 side chains in the 1SA0 structure (red) is directed at the receptor pocket unlike the 
corresponding one in 1SA1 structure (blue). 
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2.5.3 Docking results  
As far as we have been able to establish, no docking studies of CA-1 analogues into the tubulin 
structure 1SA0 or 1SA1 have been reported in the literature. Therefore an investigation of what 
combination of program and protein which was best suited for this task was undertaken. The 
programs Autodock, Glide, Gold and FRED are amongst the most used programs for performing 
docking studies and were therefore chosen.138,262-266 
 
 
Figure 45 Illustration of the correct pose versus the flipped pose of CA-1 analogues. 
 
The CA-1 analogues have a higher polarity compared to CA-4, since the B-ring have two polar 
substituents. The binding mode is considered correct when the rings of the triazole analogue are 
superimposed over the rings of colchicine, i.e. At over Ac and Bt over Bc and so on. A significant 
part of the dockings in the 1SA0 structure gave results where the triazole analogues were posed in a 
flipped mode. Ring A (TMP moiety) of the analogue was still superimposed over DAMA-
colchicine, but the Bt and Ct have been vertically flipped (Figure 45). The prevalence of the flipped 
pose was reduced by changing to the protein complex 1SA1. Energetically or scoring wise, the 
flipped pose were not always significantly different from the correct pose (Appendix Table 10). The 
reason for the increased incidence of a flipped pose in the 1SA0 structure could be explained by the 
smaller pocket and the larger polar area oriented towards the receptor pocket originating from the 
residues Thr 179 and Ser 178. 
 
For Autodock4 standard docking parameters yielded good results when docking the native ligand 
colchicine or podophyllotoxin. The parameters were optimized with the docking set (see Appendix). 
An advantageous function in Autodock4 is the cluster utility, which cluster together the various 
poses based on RMSD in a statistical diagram giving an estimation of the probability of existence. 
The x axis value describes the G score and the y axis value the population of the cluster. A good 
score has low x-value and high y-value with good energetic separation from other results. When 
docking the analogues in the 1SA0 structure, the cluster size and mean value between the correct 
pose and the flipped pose was for most of the compounds statistically different (>0.5 kcal/mol). The 
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1,4-disubstituted 1,2,3-triazoles had scoring values (mean= -6.58 (1SA0) and -6.76 (1SA1) 
kcal/mol) comparable to the 1,5-disubstituted 1,2,3-triazoles (mean = -7.29 (1SA0) and -7.19 
(1SA1) kcal/mol). Improvement of the docking poses was seen with the 1SA1 structure, there were 
no cluster with the flipped pose and the cluster with the correct docking was higher populated, but 
as with the 1SA0 structure the 1,4-triazoles gave unreasonably good scores. Generally, Autodock4 
was quite slow, but has the advantage of offering a statistical tool for analysis of the results. 
The FRED program and the 1SA0 structure gave poor results and the flipped pose was favoured, 
having better scores, over dockings which were more or less superimposed over colchicine. The 
results were significantly improved with the use of the 1SA1 structure. The 1,5-disubstituted-1,2,3-
triazole analogues of CA-1 gave good scores (mean = -83.0) while the 1,4-disubstituted 1,2,3-
triazole analogues gave low scores (mean = -53.6).  
 
The Schrödinger packaged Glide program faced equal problem as Autodock4 in docking into 1SA0, 
the flipped pose was present and with quite similar docking score to the correct pose (mean= -7.30 
(flipped) vs. -8.14 (correct) kcal/mol). An improvement of using Glide over Autodock4 was the 
docking of the 1,4-disubstituted 1,2,3-triazoles. They received low scores with Glide (mean= -5.93 
kcal/mol) in the 1SA0 structure and were not amendable in the 1SA1 structure. Using the 1SA1 
structure in Glide improved the docking compared to the 1SA0 structure. There were still presences 
of the flipped pose (compound 180, 190, and 193). An unexpectedly high score was seen with 
compounds 197 (-9.47 kcal/mol) and 180 (-9.60 kcal/mol). When superimposing these two 
compounds over those with correct pose but, significantly lower score, did not reveal any great 
difference in positioning (data not shown).  
 
Gold gave acceptable docking results with Goldscore in the 1SA0 structure. Of the 1,5-disubstituted 
1,2,3-triazoles about half of the molecules were docked in the flipped pose and their score was 
significantly different from the correct pose (mean = 61.7 (correct) vs. 52.9 (flipped)). Two of the 
1,4-disubstituted 1,2,3-triazoles (179 and 198) were found in the binding pocket of 1SA0 with their 
TMP in superimposed over that of colchicine. The program was not able to dock into the receptor 
pocket when using the Chemscore function. 
 
Gold and Goldscore function was also satisfactory with 1SA1, only one entry was found in the 
flipped pose 194 and the 1,4-disubstituted 1,2,3-triazole 198 was found in the receptor pocket. The 
score of the correct pose in the 1SA1 structure was comparable to 1SA0 (mean = 61.7 (1SA0) vs. 
65.5 (1SA1)). The Gold program was very slow, calculation time for one molecule ranges from 0.5-
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1.5 h, whereas FRED completed the docking of all the analogues within 5 min. The CPU time/cost 
with Gold is significantly higher than for FRED and Glide but comparable with Autodock4. The 
best results was obtained with FRED and the 1SA1 structure complex as it was fast and 1,5-
disubstituted 1,2,3-triazoles and 1,4-disubstituted 1,2,3-triazoles have significantly different scoring 
values. 
 
The CA-1 analogues have a higher polarity compared to CA-4, since the B-ring have two polar 
substitutions. The docking program frequently positioned these substituents towards the polar 
surface created by the residues Thr 179 and Ser 178. This leads to the ligands posing in a flipped 
mode. As seen in all the flipped docking results they all have the possibility for a hydrogen bond to 
Ser 178, a bond not seen with the analogues docked in the 1SA1 structure. 
All docking programs were able to find a conformation of the docked analogue corresponding to 
that of colchicine or podophyllotoxin where the TMP was in the same Cartesian space as that of the 
native ligand in the parent ligand-protein complex (Figure 46). In most cases this was the docking 
with the best score. Similar combretastatin triazole analogues have been docked by others who also 
managed to match the TMP moiety with colchicine.229,244-246 Unfortunately none of the programs 
were able to rank, with their scoring function, the ligands according to their in vitro tubulin 
polymerization IC50 values. The lack of correlation of in vitro tubulin inhibition and in silico results 
is most likely due to few ligands with little diversity of structure and potency making it hard for the 
scoring function to accurately discriminate between them. Molecular docking is a great tool for hit 
identification but scoring the poses remains a problem.140,267 
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Figure 46 (a) All the analogues docked in the correct pose in the 1SA0 structure (b) All the analogues docked in the 
flipped pose in the 1SA0 structure (c) All the analogues docked in the correct pose in the 1SA1 structure (d) All the 
analogues docked in the flipped pose in the 1SA1 structure. 
 
2.5.4 Minimization 
The result complexes from the Glide docking were energy minimized with Macromodel after the 
reinsertion of GDP and GTP that were removed with the protein preparation wizard. The protein-
ligand interaction was analysed with the aid of the Sitemap function in the Schrödinger package. 
The hydrophobic, hydrogen-donor and -acceptor maps were generated of the energy minimized 
protein-ligand complex (Figure 47). 
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Figure 47 Docking poses after energy minimization. Hydrogen bonds are represented by black dotted lines. 
2.5.5 Possible hydrogen bonds 
Glide was not able to rank the ligands according to their in vivo activity. Hence, a thorough 
evaluation and comparison of the bond strengths is superfluous. A brief evaluation of the possible 
hydrogen bonds in the protein-ligand complexes of CA-1 (19) and analogue 180 with 1SA0 or 
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1SA1 as well as their flipped pose will follow.  
 
In 1SA0 the 4-OMe group is a possible hydrogen bond acceptor of the thiol proton of Cys 241, 
when CA-1 (Figure 47 a, c and e) was docked in the correct binding mode. Lysine residues are 
normally protonated at physiological pH, and an ion-dipole interaction between Lys 352 
ammonium ion and 3ʹ-OH is possible. The flipped pose can acts as a hydrogen bond donor from 2ʹ-
OH to the carbonyl of Thr 179 and between 3ʹ-OH and Ser 178. The 3ʹ-OH and 3-OMe are close 
enough for H-acceptor interactions to the side chain hydroxyl group of Ser 178 and thiol proton of 
Cys 241 respectively. The only possible hydrogen bonds between CA-1 and 1SA1 structure were 
Thr 179, and the thiol proton of Cys 241 which are within distance 2ʹ-OH and 4-OMe, 
respectively.  
 
For the most biologically potent 1,2,3-triazole analogue investigated, 180 (Figure 47 b, d and f), the 
4-OMe was within distance of the thiol proton of Cys 241 to act as a hydrogen bond acceptor. A 
possible ion-dipole interaction between the ammonium ion of the Lys 352 side chain and the 3ʹ-
NH2 group was recognized. In the flipped pose the 3ʹ-NH2 group could be a hydrogen bond donor to 
the carbonyl of Ser 178 and the 3-OMe group was within distance of the thiol proton of Cys 241 
to act as hydrogen bond acceptor. In 1SA1 structure the 3ʹ-NH2 group was close enough to Thr 
179 to act as a hydrogen bond donor. The 3-OMe group was within distance of the thiol proton of 
Cys 241 to act as hydrogen bond acceptor.  
CA-1 (19) and 180 display similar interactions with the surrounding tubulin residues, this could 
rationalize their observed tubulin inhibition activity (IC50 = 3.5 and 5.2 µM). 
2.5.6 Hydrophobic interactions 
Possible hydrophobic interactions of the A-ring  
The colchicine binding site of tubulin consists of residues creating a hydrophobic pocket that 
accommodate the ligand. The residues that make up the hydrophobic space for the TMP are 
conserved for the 1SA0 correct and flipped pose, and the 1SA1 correct conformation as the TMP is 
occupying the same Cartesian space in all three modes. The residues Leu 248 and Leu 255 create 
a box for the TMP moiety together with Ala 316, Ala 317, Lys 352, and Ile 378 in all three 
dockings. Furthermore, the analogues in the correct pose in the two structures 1SA0 and 1SA1 
share hydrophobic contribution from residues Val 238, Val 351 and Ala 354. Leu 242 only 
interacts with the analogues in the correct conformation in 1SA0 structure. The TMP of the 
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analogues in the 1SA1structure interacts with Ala 250 which was also shared with the flipped pose 
in the 1SA0 structure. The TMP moiety of the flipped poses enjoys hydrophobic interactions with 
the three residues Lys 254 and Val 318 which the correct conformations do not. 
 
Possible hydrophobic interactions of the B-ring 
The hydrophobic B-ring pocket consists of the same residues in both structures for the correct 
poses. The aliphatic contributions to the B-ring in both the 1SA0 and 1SA1 come from Ala 180, 
Val 181 and the  and  carbons of Lys 352 side chain. Furthermore, residues Leu 255, Asn 
258, Met 259, Val 315 and Ala 316 also contribute. Generally the amide side chain of Asn 
258 can be seen as coplanar to the aromatic B-ring, which could indicate aliphatic interaction 
between the two, this co-planarity was not seen for the flipped pose. The only different hydrophobic 
contributing residues are Asn 350 for the 1SA0 and Leu 248 for 1SA1. 
The B-ring of the flipped poses is placed in a hydrophobic area spanned out by Ala 180, Leu 
248, Asn 258, Lys 352 and Ala 354.  
 
Possible hydrophobic interactions of the 1,2,3-triazole 
The correct pose triazole in the 1SA0 and 1SA1 structures occupies a hydrophobic pocket 
consisting of the same residues in the two structures; Leu 248, Ala 250, Lys 254, Leu 55 and 
Asn 258. Around the triazole in the flipped dockings we find aliphatic contributions from Val 
181, Leu 255, Ala 316, Met 259 and the  carbons of Lys 254 side chain. 
 
2.5.7 Conclusions 
The 1,5-disubstituted 1,2,3-triazole analogues of CA-1 were able to occupy the same Cartesian 
space as the native ligands of the tubulin complexes 1SA0 and 1SA1. This indicates that there is 
reason to expect biological activity of the docked compounds which have not yet been synthesized 
or biologically tested (compounds 194 and 195). A flipped pose was identified for the 1,5-
disubstituted 1,2,3-triazole analogues of CA-1 in the 1SA0 structure with similar docking score as 
the correct conformation. The Thr 179 and Ser 178 combined created a significantly larger polar 
surface oriented towards the binding site in the 1SA0 structure than in the 1SA1 structure. This was 
believed to contribute to the flipped pose docking results.  
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3 Conclusions 
The need for new anti-cancer drugs is apparent. Classical medicinal chemistry has for decades 
provided new chemical entities and will most likely do so in the proximal future. Nature continues 
to be a primary source for new chemical leads and inspiration towards anti-cancer agents. 
 
Targeting pCasp3/caspase-3 in cells with dysfunctional apoptotic pathway is a logical sound 
strategy both in hyper- and hypoactive disorders. Indirect activation was effectuated by PAC-1 
through relief of zinc inhibition of pCasp-3/caspase-3, though neurotoxicity emerged in the in vivo 
trials. Neuron cells isolated from chicken were found as a suitable model to study mechanisms of 
interference with apoptosis of PAC-1 and similar compounds. The two PAC-1 derivatives that were 
synthesized, 128 and 130, were more active than PAC-1 in seven cancer cell lines and was cytotoxic 
to PC12 cells in comparable concentration to PAC-1 (12).  
 
The ortho-formylation reaction using the MgCl2/Et3N base system has proven to be a practical and 
environmentally benign method as evident from its many applications. It has now been extended to 
involve also mono-protected resorcinols and estrogens, exerting good to excellent regioselectivity 
and yields in most cases. Furthermore, this reaction was a key step for the preparation of analogues 
of combretastatin A-1 and PAC-1, as well as in the total synthesis of 2ME2. 
 
The natural compound combretastatin A-1 has recently received increased attention. Replacing the 
olefinic bridge with the 1,2,3-triazole moiety yielded configurationally restricted analogues of CA-1 
(19). The 1,5-disubstiuted 1,2,3-triazole analogue 180 of combretastatin A-1 exhibited cytotoxic 
effects against several cancer cell lines in the low micromolar range. In addition, 180 exhibited 
modest inhibition of tubulin assembly with IC50-values in the low micromolar range. Molecular 
modelling studies indicated that the 1,5-disubstituted 1,2,3-triazole CA-1 analogues were 
challenging to dock into the 1SA0 structure of tubulin, and that the tubulin-podophyllotoxin 
complex (1SA1) is a better suited structure for docking of 1,5-disubstiuted 1,2,3-triazole CA-1 
analogues. These docking studies may form the basis for new analogues of CA-1.  
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4 Future perspectives 
Professor E.J. Corey’s group has synthesized potent anti-angiogenetic agents. Design of these 
compounds was inspired by cortistatin A, a natural anti-angiogenetic compound isolated from the 
marine sponge Corticulum simplex. These analogues are structurally less complex and easier to 
synthesize than the natural product. Functional studies have shown they inhibit capillary cell 
growth, migration, in vitro tube formation, and in vivo angiogenesis in the living retina of neonatal 
mice.268 
 
Figure 48 Cortistatin A and a potent derivative. 
This prompted us to investigate if 2ME2 could adopt the substitution pattern of 202. Employing the 
same procedure as to 202 to oxidized and protected 2ME2 could yield interesting compounds, such 
as 205. 
Scheme 17 Synthetic scheme for analogues of 2ME2. 
Available from the ortho-formylation reaction compound 100 can serve as a starting material. It can 
be transformed into a 2ME2 analogue by known synthetic methods and thereafter cycloaddition 
reactions can be performed with the 17-etynyl resulting in heterocyclic derivatives, such as 207.  
 
Figure 49 2ME2 analogues from compound 100. 
Further studies in our group are on-going based on the chemistry presented in this thesis and 
outlined in Scheme 17 and Figure 49. 
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5 Appendix 
5.1 General 
Unless noted otherwise, all reagents and solvents were used as purchased without further 
purification. Melting points are uncorrected. Analytical TLC was performed using silica gel 60 F254 
plates (Merck) or RP-18 F254s plates (Merck). Flash column chromatography was performed on 
silica gel 60 (40-63µm, Fluka). NMR (1H, 13C) spectra were recorded on a Bruker DPX-300 MHz 
or DPX-200 MHz spectrometer. Coupling constants (J) are reported in hertz, and chemical shifts are 
reported in parts per million (	) relative to CDCl3 (7.26 ppm for 1H and 77.00 ppm for 13C), 
DMSO-d6 (2.50 ppm for 1H and 39.43 ppm for 13C), acetonitrile-d3 (1.94 ppm for 1H and 1.32 ppm 
for 13C), CD3OD (4.87 ppm for 1H and 49.15 for 13C) or D2O (4.79 ppm for 1H). Compounds 
137,269 154,269 and 155270 are known. The western blot (Figure 32) was performed by Mona Gaarder 
with the same method as described in paper II. 
5.1.1 MTT assay 
PC12 cells were grown in DMEM supplemented with 10% foetal calf serum, 5% horse serum, 
sodium pyruvate, and penicillin/streptomycin in a 96 well plate. After 24 h the cells were treated 
with sample compound at different concentrations, dissolved in DMSO (0.1% final concentration) 
for 48 hours. MTT solution was made by dissolving 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium in PBS and then filtered to a final concentration of 5 mg/mL. 50 µL of MTT solution is 
added to each well and the cells were allowed to incubate for 1 h at 37°C. After removing of 
medium, the cells and dye crystals were solubilized by adding 100 µl of DMSO, and the absorption 
was measured at 570 nm by an ELISA reader. 
5.1.2 Synthesis of starting materials 
3-Bromo-2,6-dihydroxybenzaldehyde (158). To a stirring solution of 3-bromo-6-((tert-
butyldimethylsilyl)oxy)-2-hydroxybenzaldehyde (149c, 144 mg, 0.43 mmol) in THF (2 mL) at 0 °C 
TBAF (0.52 mL, 1M) was added. The solution was stirred for 10 min before Et2O (10 mL) and HCl 
(10 mL, 1M) were added. The reaction mixture was transferred to a separatory funnel and the aq. 
phase was back extracted with Et2O (3x 5 mL). The combined organic phases was dried over 
anhydrous magnesium sulphate and concentrated in vacou. The yellow crude product was purified 
by chromatography to yield 158 (70%); mp 161-162 °C (heptane); Rf = 0.32 (6:4, heptane:EtOAc); 
1H NMR (300 MHz, MeOH) δ 10.25 (s, 1H), 7.49 (d, J = 8.8 Hz, 1H), 6.31 (d, J = 8.8 Hz, 1H); 13C 
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NMR (75 MHz, MeOH) δ = 195.44, 162.87, 159.91, 142.06, 112.14, 108.86, 99.60.  
 
3-((2,3-Dimethylbutan-2-yl)dimethylsilyloxy)phenol (139). To a solution of resorcinol (220 mg, 2 
mmol) in DMF (3 mL), DBU (334 mg, 2.2 mmol) and chloro(2,3-dimethylbutan-2-
yl)dimethylsilane (392 mg, 2.2 mmol) were added and stirred over night. The crude reaction 
mixture was transferred directly to silica for column chromatography (9:1, hexane:EtOAc). 
Colourless oil (20%); Rf = 0.48 (8:2, hexane:EtOAc); 1H NMR (300 MHz, CDCl3) δ = 7.05 (t, J = 
8.1, 1H), 6.41 (ddd, J = 1.3, 2.2, 8.0, 2H), 6.33 (t, J = 2.3, 1H), 4.92 (s, 1H), 1.71 (m, 1H), 0.93 (t, J 
= 3.4, 12H), 0.21 (s, 6H). 13C NMR (75 MHz, CDCl3) δ = 156.80, 156.49, 129.89, 112.76, 108.33, 
107.60, 34.11, 25.02, 20.11, 18.54, -2.46. 
 
(8R,9S,13S,14S)-3-Hydroxy-2-methoxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-6H-
cyclopenta[a]phenanthren-17(14H)-one (203). 2-Methoxyestradiol (3.0 g, 10 mmol) was placed 
in a 250 mL round-bottomed flask that was equipped with reflux condenser. Toluene (150 mL), 
aluminium isopropoxide (10 g, 50 mmol) and cyclohexanone (30 mL, mmol) were added to the 
suspension. The entire reaction mixture was heated at reflux (120 °C) for 20 h. The reaction mixture 
was allowed to cool to room temperature and the suspension was treated with 3 N HCl until the gel-
emulsion dissolved and the phases separated. The aqueous layer was extracted with Et2O (3x 50 
mL) and EtOAc (3x 50 mL). The combined organic extracts were dried over anhydrous magnesium 
sulfate, concentrated in vacuo, and distilled (120-140°C) under reduced pressure. The resulting 
yellow crude was triturated with boiling hexane and left in freezer over night. The organic phase 
was decantated of and the colourless powder was washed with additional cold hexane before drying 
on high vacuum pump affording 2-methoxyestrone. Colourless solid (75%); mp 184-185 °C 
(hexane) (lit.121 mp 188-191 °C);  Rf = 0.25 (7:3, hexane:EtOAc); 1H NMR (300 MHz, CDCl3) δ = 
6.79 (s, 1H), 6.66 (s, 1H), 3.86 (s, 3H), 2.91 – 2.73 (m, 2H), 2.51 (dd, J = 18.4, 8.4 Hz, 1H), 2.43 – 
2.32 (m, 1H), 2.32 – 1.90 (m, 5H), 1.75 – 1.22 (m, 6H), 0.92 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 
= 144.65, 143.59, 131.05, 129.22, 114.61, 108.00, 55.99, 50.34, 47.95, 44.21, 38.29, 35.83, 31.56, 
28.80, 26.55, 26.17, 21.51, 13.82. 
 
(8R,9S,13S,14S)-2-Methoxy-3-(methoxymethoxy)-13-methyl-7,8,9,11,12,13,15,16-octahydro-
6H-cyclopenta[a]phenanthren-17(14H)-one (204). Compound 203 (800 mg, 2.6 mmol) was 
dissolved in THF under argon. Diisopropylethylamine (1.33 mL, 7.8 mmol) was added dropwise 
followed by chloromethyl methyl ether (0.49 mL, 6.5 mmol). The reaction was heated to reflux and 
stirred over night. Brine (30 mL) was added and the aqueous layer was extracted with 
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dichloromethane (30 mL). The combined organic layers were washed with acetic acid (2x 15 mL, 
10%), sat. NaHCO3 (15 mL) and brine (30 mL), dried over anhydrous magnesium sulfate and the 
solvent was removed in vacuo. The product was purified by chromatography (7:3, hexane:EtOAc). 
Pale yellow solid (76% yield); mp 114-115 °C (hexane:EtOAc) (lit.271 mp 117 °C); Rf = 0.25 
(hexane:EtOAc 7:3); 1H NMR (300 MHz, CDCl3) δ = 6.88 (s, 1H), 6.83 (s, 1H), 5.19 (s, 2H), 3.85 
(s, 3H), 3.51 (s, 3H), 2.89 – 2.78 (m, 2H), 2.50 (dd, J = 18.4, 8.4 Hz, 1H), 2.43 – 1.91 (m, 6H), 1.70 
– 1.31 (m, 7H), 0.91 (s, 3H); 13C NMR (75 MHz, CDCl3) δ = 147.71, 144.50, 133.45, 128.73, 
116.82, 109.28, 95.47, 56.10, 56.01, 50.36, 47.94, 44.30, 38.22, 35.83, 31.58, 28.90, 26.58, 26.05, 
21.52, 13.83. 
5.1.3 ortho-Formylation products 
General procedure for ortho-formylation of phenols 
To a dry THF solution (10 mL) of the phenol (1 mmol), anhydrous magnesium chloride (0.19 g, 2 
mmol), triethylamine (0.20 g, 2 mmol), paraformaldehyde (90 mg, 3 mmol) were added. The 
reaction mixture was heated to reflux under an argon atmosphere for 1-4 h, and monitored by TLC 
(hexane:EtOAc, 8:2). After complete consumption of the phenol, the reaction mixture was cooled 
and diluted with Et2O (20 mL). The organic layer was washed successively with HCl (1M, 2x 10 
mL) and water (2x 10 mL), and then dried (MgSO4). The product was purified by column 
chromatography using hexane:EtOAc (95:5 to 70:30). 
 
3-Allyl-2-hydroxybenzaldehyde (105). Pale yellow oil (78%); Rf = 0.31 (95:5, hexane:EtOAc); 1H 
NMR (300 MHz, CDCl3) δ = 11.28 (s, 1H), 9.87 (s, 1H), 7.45 - 7.35 (m, 2H), 6.95 (t, J = 7.6, 1H), 
6.06 - 5.89 (m, 1H), 5.13 - 5.02 (m, 2H), 3.41 (dd, J = 5.1, 8.5, 2H); 13C NMR (75 MHz, CDCl3) δ 
= 196.67, 159.49, 137.09, 135.73, 131.85, 128.77, 120.25, 119.53, 116.21, 33.00. 
 
3-Ethyl-2-hydroxybenzaldehyde (106). Colourless oil (71%); Rf = 0.68 (9:1, hexane:EtOAc); 1H 
NMR (300 MHz, CDCl3) δ = 11.29 (s, 1H), 9.87 (s, 1H), 7.40 (dt, J = 4.3, 1.9 Hz, 2H), 6.95 (t, J = 
7.6 Hz, 1H), 2.70 (q, J = 7.5 Hz, 2H), 1.23 (t, J = 7.5 Hz, 3H);  13C NMR (75 MHz, CDCl3) δ = 
196.75, 159.61, 136.19, 132.66, 131.31, 120.06, 119.45, 22.17, 13.61.  
 
2-Hydroxy-3-propylbenzaldehyde (107). Colourless oil (85%); Rf = 0.34 (95:5, hexane:EtOAc); 
1H NMR (300 MHz, CDCl3) δ = 11.25 (d, J = 0.5, 1H), 9.86 (s, 1H), 7.47 - 7.27 (m, 2H), 6.92 (t, J 
= 7.6, 1H), 2.73 - 2.49 (m, 2H), 1.63 (dq, J = 7.4, 14.8, 2H), 0.94 (t, J = 7.4, 3H); 13C NMR (75 
MHz, CDCl3) δ = 196.77, 159.79, 137.14, 131.45, 131.22, 120.19, 119.33, 31.09, 22.49, 13.90. 
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2-Hydroxy-3-isopropylbenzaldehyde (108). Colourless oil (63%); Rf = 0.50 (9:1, hexane:EtOAc); 
1H NMR (300 MHz, CDCl3) δ = 11.38 (s, 1H), 9.88 (s, 1H), 7.47 (dd, J = 7.5, 1.6 Hz, 1H), 7.40 
(dd, J = 7.7, 1.7 Hz, 1H), 6.99 (t, J = 7.6 Hz, 1H), 3.47 – 3.29 (m, 1H), 1.26 (s, 3H), 1.24 (s, 3H); 
13C NMR (75 MHz, CDCl3) δ = 196.89, 159.18, 137.04, 133.60, 131.26, 120.10, 119.55, 26.17, 
22.23. 
 
3-tert-Butyl-2-hydroxybenzaldehyde (109). Colourless oil (71%); Rf = 0.73 (95:5, 
hexane:EtOAc); 1H NMR (300 MHz, CDCl3) δ = 11.77 (s, 1H), 9.86 (s, 1H), 7.51 (dd, J = 1.4, 7.7, 
1H), 7.38 (dd, J = 1.7, 7.7, 1H), 6.93 (t, J = 7.7, 1H), 1.40 (s, 9H); 13C NMR (75 MHz, CDCl3) δ = 
197.14, 161.17, 138.16, 134.09, 131.96, 120.57, 119.17, 34.82, 29.15.  
 
2-Hydroxy-3-phenyl-benzaldehyde (110). Yellow solid (84%); mp 47-48 °C (EtOAc) (lit.167 47-
48 °C); Rf = 0.56 (95:5, hexane:EtOAc); 1H NMR (300 MHz, CDCl3) δ = 11.56 (s, 1H), 9.96 (s, 
1H), 7.61 (m, 4H), 7.47 (m, 2H), 7.39 (m, 1H), 7.12 (t, J = 7.6 Hz, 1H); 13C NMR (75 MHz, 
CDCl3) δ = 196.82, 158.82, 137.77, 136.22, 133.16, 130.40, 129.21, 128.25, 127.63, 120.79, 
119.89. 
 
3-Cyclopentyl-2-hydroxybenzaldehyde (111). Colourless oil (82%); Rf = 0.45 (95:5, 
hexane:EtOAc); 1H NMR (300 MHz, CDCl3) δ = 11.38 (s, 1H), 9.88 (s, 1H), 7.47 (dd, J = 7.5, 1.6 
Hz, 1H), 7.38 (dd, J = 7.7, 1.7 Hz, 1H), 6.96 (t, J = 7.6 Hz, 1H), 3.38 (m, 1H), 2.07 (m, 2H), 1.70 
(m, 6H); 13C NMR (75 MHz, CDCl3) δ = 196.83, 159.79, 134.82, 134.18, 131.21, 120.11, 119.43, 
38.33, 32.63, 25.35. 
 
3-Cyclohexyl-2-hydroxybenzaldehyde (112). Colourless solid (73%); mp 45-46 °C; Rf = 0.45 
(95:5, hexane:EtOAc); 1H NMR (300 MHz, CDCl3) δ = 11.39 (s, 1H), 9.88 (s, 1H), 7.45 (dd, J = 
7.5, 1.6 Hz, 1H), 7.39 (dd, J = 7.7, 1.7 Hz, 1H), 6.98 (t, J = 7.6 Hz, 1H), 3.01 (tt, J = 11.2, 2.9 Hz, 
1H), 1.81 (m, 5H), 1.36 (m, 5H); 13C NMR (75 MHz, CDCl3) δ = 196.91, 159.16, 136.26, 134.10, 
131.19, 120.08, 119.56, 36.09, 32.76, 26.84, 26.25. 
 
3-Benzyl-2-hydroxybenzaldehyde (113). Pale yellow solid (70%); mp 33-34°C; Rf = 0.50 (95:5, 
hexane:EtOAc); 1H NMR (300 MHz, CDCl3) δ = 11.37 (s, 1H), 9.89 (s, 1H), 7.44 (dd, J = 7.7, 1.6 
Hz, 1H), 7.28 (m, 6H), 6.95 (t, J = 7.6 Hz, 1H), 4.04 (s, 2H); 13C NMR (75 MHz, CDCl3) δ = 
196.66, 159.49, 139.83, 137.48, 131.93, 129.94, 128.93, 128.43, 126.16, 120.30, 119.53, 34.75. 
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3,5-di-tert-Butyl-2-hydroxybenzaldehyde (114). Colourless solid (55%); mp 59-61°C (lit.272 mp 
61-63 °C (EtOH)); Rf = 0.76 (95:5, hexane:EtOAc); 1H NMR (300 MHz, CDCl3) δ 11.64 (s, 1H), 
9.86 (s, 1H), 7.58 (d, J = 2.3, 1H), 7.34 (d, J = 2.4, 1H), 1.41 (s, 9H), 1.31 (s, 9H); 13C NMR (75 
MHz, CDCl3) δ 197.79, 159.49, 142.01, 137.96, 132.33, 128.27, 120.36, 35.43, 34.66, 31.74, 
29.67. 
 
2-Hydroxy-1-naphthaldehyde (115). Yellow solid (49%); mp 78-79 °C (lit.273 mp 79 °C); Rf = 
0.29 (9:1, hexane:EtOAc); 1H NMR (300 MHz, CDCl3) δ 13.14 (s, 1H), 10.80 (s, 1H), 8.33 (d, J = 
8.5, 1H), 7.96 (d, J = 9.1, 1H), 7.79 (d, J = 8.1, 1H), 7.60 (ddd, J = 1.4, 7.0, 8.5, 1H), 7.42 (ddd, J = 
1.0, 7.0, 8.0, 1H), 7.13 (d, J = 9.1, 1H); 13C NMR (75 MHz, CDCl3) δ 193.16, 164.82, 139.05, 
132.76, 129.39, 129.03, 127.68, 124.42, 119.07, 118.50, 111.16. 
 
4-Hydroxybenzo[d][1,3]dioxole-5-carbaldehyde (116). Colourless solid (97%); mp 113-115 °C 
(lit.177 mp 113-115 °C); Rf = 0.62 (7:3, hexane:EtOAc); 1H NMR (200 MHz, CDCl3): δ = 10.97 (s, 
1H), 9.71 (s, 1H), 7.14 (d, J = 8.2 Hz, 1H), 6.56 (d, J = 8.2 Hz, 1H), 6.08 (s, 1H). 13C NMR (75 
MHz, CDCl3): δ = 195.06, 155.13, 145.49, 134.10, 30.43, 118.25, 102.80, 101.95.  
 
4-Formyl-3-hydroxyphenol acetate (136). Colourless solid (20%); mp 48-49 °C (CHCl3) (lit.274 
49-50 (EtOH)); Rf = 0.38 (9:1, hexane:EtOAc); 1H NMR (300 MHz, CDCl3): 	 = 11.19 (s, 1H), 
9.82 (s, 1H), 7.55 (d, J = 8.2 Hz, 1H), 6.75 (m, 2H), 2.29 (s, 3H); 13C NMR (75 MHz, CDCl3): 	 = 
170.70, 156.75, 151.17, 129.99, 113.31, 113.19, 109.05, 21.04. 
 
4-Formyl-3-hydroxyphenol pivalate (137). Colourless solid (40%); mp 63-64 oC (hexane); Rf = 
0.38 (8:2, hexane:EtOAc); 1H NMR (200 MHz, CDCl3): 	 = 11.18 (s, 1H), 9.82 (s, 1H), 7.53 (dd, J 
= 8.2, 0.5 Hz, 1H), 6.72 (m, 2H), 1.33 (s, 9H); 13C NMR (50 MHz, CDCl3): 	 = 195.41, 176.03, 
163.10, 157.90, 134.84, 118.51, 113.85, 110.58, 39.26, 26.97. 
 
tert-Butyl 4-formyl-3-hydroxyphenyl carbonate (138). Colourless solid (30%); mp 72-73 °C 
(hexane); Rf = 0.43 (7:3, hexane:EtOAc); 1H NMR (200 MHz, CDCl3): 	 = 11.19 (s, 1H), 9.83 (s, 
1H), 7.54 (dd, J = 7.8, 1.1 Hz, 1H), 6.84 (m, 2H), 1.54 (s, 9H); 13C NMR (50 MHz, CDCl3) δ = 
195.37, 163.06, 157.47, 150.39, 134.88, 118.43, 113.30, 110.08, 84.45, 27.56. 
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4-((2,3-Dimethylbutan-2-yl)dimethylsilyloxy)-2-hydroxybenzaldehyde (139). Brown oil (66 %); 
Rf = 0.38 (9:1, hexane:EtOAc);  1H NMR (300 MHz, CDCl3) δ = 11.31 (s, 1H), 9.69 (s, 1H), 7.37 
(d, J = 8.5, 1H), 6.44 (dd, J = 2.2, 8.5, 1H), 6.36 (d, J = 2.1, 1H), 1.75 – 1.62 (m, 1H), 0.91 (d, J = 
7.0, 13H), 0.27 (s, 6H); 13C NMR (75 MHz, CDCl3) δ = 194.46, 164.05, 163.60, 135.37, 115.75, 
113.10, 107.65, 34.00, 25.12, 19.97, 18.46, -2.42. 
 
2-Hydroxy-4,6-dimethoxybenzaldehyde (156b). Colourless solid (21%); mp 70-71 °C (CHCl3) 
(lit.275 mp 71 °C); Rf = 0.48 (6:4, hexane:EtOAc); 1H NMR (300 MHz, CDCl3) δ = 12.49 (s, 1H), 
10.07 (s, 1H), 6.00 (d, J = 2.1 Hz, 1H), 5.89 (d, J = 1.9 Hz, 1H), 3.82 (s, 3H), 3.80 (s, 3H); 13C 
NMR (75 MHz, CDCl3) δ = 191.76, 168.08, 166.26, 163.48, 105.94, 92.86, 90.48, 55.65, 55.63. 
5.1.4 PAC-1 derivatives 
General procedure for the synthesis of PAC-1 analogues 
A 100 mL round-bottom flask was charged with salicylaldehyde (1 mmol, 1 eqv.) and EtOH (10 
mL). To the stirring solution (4-Benzylpiperazino)acetic acid hydrazide (120, 1.1 mmol) and 12M 
HCl (10 µL in 40 mL of EtOH) were added. The reaction was heated at reflux for 48 hrs. The 
reaction mixture was cooled and then concentrated via rotary evaporation and crystallized from 
EtOH/hexane. Reactions were monitored by TLC on RP-18 F254s plates (Merck).  
 
(E)-2-(4-Benzylpiperazin-1-yl)-N'-(3-ethyl-2-hydroxybenzylidene)acetohydrazide (121). 
Colourless solid (>25%); mp 118-119 °C (hexane); Rf = 0.37 (9:1, ACN:MeOH); 1H NMR (300 
MHz, CDCl3) δ = 11.19 (s, 1H), 10.01 (s, 1H), 8.42 (s, 1H), 7.38 – 7.27 (m, 5H), 7.20 (dd, J = 7.4, 
1.1 Hz, 1H), 7.06 (dd, J = 7.7, 1.6 Hz, 1H), 6.84 (t, J = 7.5 Hz, 1H), 3.56 (s, 2H), 3.19 (s, 2H), 2.72 
(q, J = 7.5 Hz, 2H), 2.67 – 2.42 (m, 8H), 1.23 (t, J = 7.5 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ = 
165.71, 156.49, 151.40, 132.20, 131.46, 129.14, 128.63, 128.29, 127.25, 118.92, 116.62, 62.77, 
60.89, 53.57, 52.90, 22.90, 13.82. HRMS calcd. for C22H28N4O2 (M+): 380.2212, found: 380.2209. 
 
(E)-2-(4-Benzylpiperazin-1-yl)-N'-(2-hydroxy-3-propylbenzylidene)acetohydrazide (122). 
Colourless solid (56%); mp 134-135 °C (hexane); Rf = 0.66 (8:2:0.1, ACN:MeOH:CH3COOH);  1H 
NMR (200 MHz, CDCl3) δ = 11.19 (s, 1H), 10.02 (s, 1H), 8.41 (s, 1H), 7.42 – 7.27 (m, 5H), 7.17 
(dd, J = 7.4, 1.3 Hz, 1H), 7.06 (dd, J = 7.7, 1.6 Hz, 1H), 6.83 (t, J = 7.5 Hz, 1H), 3.56 (s, 2H), 3.19 
(s, 2H), 2.88 – 2.39 (m, 11H), 1.85 – 1.49 (m, 2H), 0.96 (t, J = 7.3 Hz, 3H); 13C NMR (75 MHz, 
CDCl3) δ = 165.67, 156.62, 151.46, 132.41, 130.67, 129.17, 128.72, 128.31, 127.30, 118.78, 
116.68, 100.49, 62.75, 60.87, 53.52, 52.88, 31.84, 22.61, 14.01; HRMS calcd. for C23H30N4O2 (M+): 
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394.2369, found: 394.2365. 
 
(E)-2-(4-Benzylpiperazin-1-yl)-N'-(2-hydroxy-3-isopropylbenzylidene)acetohydrazide (123). 
Colourless solid (48%); mp 138-139 °C (hexane); Rf = 0.37 (9:1, ACN:MeOH); 1H NMR (300 
MHz, CDCl3) δ = 11.28 (s, 1H), 10.04 (s, 1H), 8.40 (s, 1H), 7.39 – 7.22 (m, 7H), 7.06 (dd, J = 7.7, 
1.5 Hz, 1H), 6.87 (t, J = 7.6 Hz, 1H), 3.57 (s, 2H), 3.48 – 3.34 (m, 1H), 3.20 (s, 2H), 2.80 – 2.42 (m, 
8H), 1.26 (s, 3H), 1.24 (s, 3H);  13C NMR (75 MHz, CDCl3) δ = 165.68, 156.03, 151.57, 136.51, 
129.18, 128.69, 128.51, 128.31, 127.31, 118.99, 116.63, 62.75, 60.86, 53.51, 52.87, 26.63, 22.32; 
HRMS calcd. for C23H30N4O2 (M+): 394.2369, found: 394.237. 
 
(E)-2-(4-Benzylpiperazin-1-yl)-N'-(3-tert-butyl-2-hydroxybenzylidene)acetohydrazide (124). 
Colourless fluffy solid (61%); mp 180-181 °C (hexane); Rf = 0.70 (9:1:0.1, 
ACN:MeOH:CH3COOH); 1H NMR (300 MHz, CDCl3) δ = 11.53 (s, 1H), 10.01 (s, 1H), 8.41 (s, 
1H), 7.38 – 7.27 (m, 6H), 7.07 (dd, J = 7.6, 1.5 Hz, 1H), 6.84 (t, J = 7.7 Hz, 1H), 3.56 (s, 2H), 3.20 
(s, 2H), 2.77 – 2.45 (m, 8H), 1.44 (s, 9H); 13C NMR (75 MHz, CDCl3) δ = 165.69, 157.83, 151.91, 
137.62, 129.27, 129.12, 128.28, 127.24, 118.57, 117.13, 62.78, 60.89, 53.58, 52.92, 34.90, 29.30; 
HRMS calcd. for C24H32N4O2 (M+): 408.2525, found: 408.2510. 
 
(E)-2-(4-Benzylpiperazin-1-yl)-N'-(3,5-di-tert-butyl-2-hydroxybenzylidene)acetohydrazide 
(125). Colourless fluffy solid (52%); mp 193-194 °C (hexane); Rf = 0.52 (9:1:0.1, 
ACN:MeOH:CH3COOH); 1H NMR (300 MHz, CDCl3) δ = 11.32 (s, 1H), 9.99 (s, 1H), 8.44 (s, 
1H), 7.38 (d, J = 2.3 Hz, 1H), 7.31 (dt, J = 4.4, 2.8 Hz, 5H), 7.05 (d, J = 2.4 Hz, 1H), 3.56 (s, 2H), 
3.19 (s, 2H), 2.68 – 2.49 (m, 8H), 1.44 (s, 9H), 1.30 (s, 9H); 13C NMR (75 MHz, CDCl3) δ = 
165.60, 155.56, 152.63, 140.75, 136.89, 129.14, 128.30, 127.26, 126.88, 125.65, 116.32, 62.79, 
60.90, 53.57, 52.93, 35.10, 34.12, 31.45, 29.38; HRMS calcd. for C28H40N4O2 (M+): 464.3151, 
found: 464.3157. 
 
(E)-2-(4-Benzylpiperazin-1-yl)-N'-(3-cyclopentyl-2-hydroxybenzylidene)acetohydrazide (126). 
Colourless solid (75%); mp 141-142 °C (hexane); Rf = 0.50 (9:1:0.1, ACN:MeOH:CH3COOH); 1H 
NMR (300 MHz, CDCl3) δ = 11.27 (s, 1H), 10.10 (s, 1H), 8.42 (s, 1H), 7.38 – 7.22 (m, 6H), 7.05 
(dd, J = 7.7, 1.6 Hz, 1H), 6.85 (t, J = 7.6 Hz, 1H), 3.60 (s, 2H), 3.49 – 3.33 (m, 1H), 3.21 (s, 2H), 
2.75 – 2.51 (m, 8H), 2.14 – 1.97 (m, 2H), 1.88 – 1.50 (m, 6H); 13C NMR (75 MHz, CDCl3) δ = 
165.56, 156.60, 151.59, 134.13, 129.32, 128.52, 128.38, 118.87, 116.60, 62.58, 60.70, 53.21, 52.71, 
38.93, 32.56, 25.38: HRMS calcd. for C25H32N4O2 (M+): 420.2525, found: 420.2527. 
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(E)-2-(4-Benzylpiperazin-1-yl)-N'-(3-cyclohexyl-2-hydroxybenzylidene)acetohydrazide (127). 
Colourless solid (56%); mp 175-177 °C (hexane); Rf = 0.29 (9:1, ACN:MeOH);  1H NMR (300 
MHz, CDCl3) δ = 11.30 (s, 1H), 10.01 (s, 1H), 8.39 (s, 1H), 7.38 – 7.26 (m, 5H), 7.24 (dd, J = 7.6, 
1.2 Hz, 1H), 7.04 (dd, J = 7.7, 1.6 Hz, 1H), 6.86 (t, J = 7.6 Hz, 1H), 3.55 (s, 2H), 3.19 (s, 2H), 3.13 
– 2.99 (m, 1H), 2.76 – 2.43 (m, 8H), 1.96 – 1.70 (m, 5H), 1.57 – 1.16 (m, 5H); 13C NMR (75 MHz, 
CDCl3) δ = 165.66, 155.99, 151.49, 135.74, 129.17, 129.13, 128.41, 128.29, 127.25, 118.99, 
116.61, 62.78, 60.89, 53.57, 52.92, 36.67, 32.84, 26.97, 26.39; HRMS calcd. for C26H34N4O2 (M+): 
434.2682, found: 434.2669. 
 
(E)-2-(4-Benzylpiperazin-1-yl)-N'-(3-ethoxy-2-hydroxybenzylidene)acetohydrazide (128). 
Colourless solid (75%); mp 97-99 °C (hexane); Rf = 0.59 (9:1:0.1, ACN:MeOH:CH3COOH); 1H 
NMR (300 MHz, CDCl3) δ = 10.79 (s, 1H), 10.06 (s, 1H), 8.49 (s, 1H), 7.30 (m, 5H), 6.92 (td, J = 
8.1, 1.7 Hz, 2H), 6.83 (q, J = 8.2 Hz, 1H), 4.12 (q, J = 7.0 Hz, 2H), 3.56 (s, 2H), 3.19 (s, 2H), 2.61 
(m, 8H), 1.46 (t, J = 7.0 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ = 165.86, 150.76, 148.48, 147.42, 
137.16, 129.21, 128.29, 127.31, 122.46, 119.00, 117.76, 115.58, 64.75, 62.68, 60.85, 53.42, 52.79, 
14.84; HRMS calcd. for C22H28N4O3 (M+): 396.2161, found: 396.2170. 
 
(E)-2-(4-Benzylpiperazin-1-yl)-N'-((2-hydroxy-[1,1'-biphenyl]-3-yl)methylene)acetohydrazide 
(129). Colourless solid (57%); mp 157-158 °C (hexane); Rf = 0.79 (7:2:0.1, 
ACN:MeOH:CH3COOH); 1H NMR (300 MHz, CDCl3) δ = 11.47 (s, 1H), 10.06 (s, 1H), 8.53 (s, 
1H), 7.67 – 7.57 (m, 2H), 7.50 – 7.26 (m, 9H), 7.22 (dd, J = 7.7, 1.6 Hz, 1H), 6.99 (t, J = 7.6 Hz, 
1H), 3.54 (d, J = 16.0 Hz, 2H), 3.19 (s, 2H), 2.91 – 2.27 (m, 8H); 13C NMR (75 MHz, CDCl3) δ = 
165.82, 155.65, 151.16, 137.70, 137.55, 132.97, 130.31, 129.89, 129.35, 129.05, 128.23, 128.01, 
127.13, 127.11, 119.29, 117.55, 62.80, 60.88, 53.63, 52.92; HRMS calcd. for C26H28N4O2 (M+): 
428.2212, found: 428.2219. 
 
(E)-N'-(3-Benzyl-2-hydroxybenzylidene)-2-(4-benzylpiperazin-1-yl)acetohydrazide (130). 
Colourless solid (88%); mp 133-135 °C (hexane); Rf = 0.37 (9:1, ACN:MeOH); 1H NMR (300 
MHz, CDCl3) δ = 11.30 (s, 1H), 10.05 (s, 1H), 8.38 (s, 1H), 7.50 – 6.97 (m, 12H), 6.82 (t, J = 7.5 
Hz, 1H), 4.05 (s, 2H), 3.57 (s, 2H), 3.19 (s, 2H), 2.87 – 2.25 (m, 8H); 13C NMR (75 MHz, CDCl3) δ 
= 165.75, 156.39, 151.20, 140.62, 137.48, 132.70, 129.32, 129.18, 129.12, 128.95, 128.27, 128.25, 
127.23, 125.85, 118.97, 116.91, 62.77, 60.88, 53.56, 52.89, 35.45; HRMS calcd. for C27H30N4O2 
(M+): 442.2369, found: 442.2370. 
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(E)-2-(4-Benzylpiperazin-1-yl)-N'-(2-hydroxy-3-nitrobenzylidene)acetohydrazide (131). Yellow 
solid (62%); mp 163-165 °C (hexane); Rf = 0.71 (9:1:0.1, ACN:MeOH:CH3COOH); 1H NMR (300 
MHz, CDCl3) δ = 10.38 (s, 2H), 8.60 (s, 1H), 8.15 (dd, J = 7.7, 1.0 Hz, 1H), 8.08 (dd, J = 8.3, 1.3 
Hz, 1H), 7.39 – 7.20 (m, 5H), 7.00 (t, J = 8.0 Hz, 1H), 3.55 (s, 2H), 3.21 (s, 2H), 2.78 – 2.42 (m, 
8H); 13C NMR (75 MHz, CDCl3) δ = 166.53, 153.21, 143.25, 137.66, 135.09, 134.99, 129.06, 
128.24, 127.16, 126.92, 123.44, 119.56, 62.78, 60.94, 53.62, 52.90; HRMS calcd. for C20H23N5O4 
(M+): 397.1750, found: 397.1746. 
 
(E)-2-(4-Benzylpiperazin-1-yl)-N'-((2-hydroxynaphthalen-1-yl)methylene)acetohydrazide 
(132). Yellow solid (95%); mp 99-101 °C (hexane); Rf = 0.33 (9:1, ACN:MeOH); 1H NMR (300 
MHz, CDCl3) δ = 12.37 (s, 1H), 10.22 (s, 1H), 9.35 (s, 1H), 7.99 (d, J = 8.5 Hz, 1H), 7.77 (dd, J = 
8.1, 4.5 Hz, 2H), 7.55 – 7.44 (m, 1H), 7.40 – 7.27 (m, 6H), 7.21 (d, J = 9.0 Hz, 1H), 3.59 (s, 2H), 
3.24 (s, 2H), 2.79 – 2.49 (m, 8H); 13C NMR (75 MHz, CDCl3) δ = 165.77, 159.08, 147.71, 137.31, 
133.15, 131.98, 129.18, 129.07, 128.29, 128.04, 127.40, 127.29, 123.41, 119.81, 119.35, 107.77, 
62.72, 60.92, 53.53, 52.83; HRMS calcd. for C24H26N4O2 (M+): 402,2056, found: 402.2055. 
 
(E)-N'-(Benzo[d][1,3]dioxol-4-ylmethylene)-2-(4-benzylpiperazin-1-yl)acetohydrazide (133). 
Colourless solid (76%); mp 168-169 °C (hexane); Rf = 0.58 (8:2:0.1, ACN:MeOH:CH3COOH); 1H 
NMR (300 MHz, CDCl3) δ = 10.10 (s, 1H), 8.40 (s, 1H), 7.43 – 7.27 (m, 6H), 6.90 – 6.81 (m, 2H), 
6.05 (s, 2H), 6.05 (s, 2H), 3.51 (d, J = 18.5 Hz, 2H), 3.18 (s, 2H), 2.95 – 2.39 (m, 8H); 13C NMR 
(75 MHz, CDCl3) δ = 166.27, 147.84, 146.41, 143.34, 129.05, 128.23, 127.14, 121.74, 119.62, 
116.10, 109.85, 101.45, 62.79, 61.02, 53.56, 52.94; HRMS calcd. for C21H24N4O3 (M+): 380.1848, 
found: 380.1864. 
 
(E)-2-(4-Benzylpiperazin-1-yl)-N'-(2,3-dimethoxybenzylidene)acetohydrazide (134). Colourless 
solid (90%); mp 139-141 °C (hexane); Rf = 0.63 (9:1:0.1, ACN:MeOH:CH3COOH); 1H NMR (200 
MHz, CDCl3) δ = 10.08 (s, 1H), 8.44 (s, 1H), 7.69 (dd, J = 7.9, 1.5 Hz, 1H), 7.40 – 7.27 (m, 5H), 
7.07 (t, J = 8.0 Hz, 1H), 6.95 (dd, J = 8.1, 1.6 Hz, 1H), 3.90 (s, 3H), 3.89 (s, 3H), 3.57 (s, 2H), 3.20 
(s, 2H), 2.80 – 2.44 (m, 8H); 13C NMR (75 MHz, CDCl3) δ = 166.20, 152.51, 148.48, 143.76, 
129.12, 128.26, 127.19, 124.21, 118.64, 114.09, 62.78, 61.73, 61.04, 55.76, 53.58, 52.91: HRMS 
calcd. for C22H28N4O3 (M+): 396.2161, found: 396.2157. 
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(E)-2-(4-Benzylpiperazin-1-yl)-N'-((4-hydroxybenzo[d][1,3]dioxol-5-yl)methylene)aceto 
hydrazide (135). Colourless solid (65%); mp 120-123 °C (hexane); Rf = 0.46 (9:1:0.1 
ACN:MeOH:CH3COOH); 1H NMR (300 MHz, CDCl3) δ = 10.00 (s, 1H), 8.38 (s, 1H), 7.28 (d, J = 
12.8 Hz, 6H), 6.75 (d, J = 8.1 Hz, 1H), 6.45 (d, J = 8.1 Hz, 1H), 6.01 (s, 2H), 3.52 (d, J = 9.0 Hz, 
2H), 3.17 (s, 2H), 2.57 (d, J = 25.9 Hz, 8H); 13C NMR (75 MHz, CDCl3) δ = 165.81, 151.56, 
150.92, 142.80, 137.44, 134.40, 129.11, 128.22, 127.18, 125.54, 114.11, 101.96, 100.88, 62.74, 
60.85, 53.52, 52.83; HRMS calcd. for C21H24N4O4 (M+): 396.1798, found: 396.1796. 
 
(E)-2-(4-Benzylpiperazin-1-yl)-N'-(3-bromo-2,6-dihydroxybenzylidene)acetohydrazide (159). 
Yellow semi solid (33%); Rf = 0.32 (9:1, ACN:MeOH); 1H NMR (300 MHz, CD3OD) δ = 8.76 (s, 
1H), 7.47 – 7.20 (m, 7H), 3.84 (s, 2H), 3.25 (s, 2H), 2.94 (s, 1H), 2.90 – 2.63 (m, 8H); 13C NMR 
(75 MHz, CD3CN) δ = 166.87, 157.74, 155.77, 146.19, 138.77, 135.51, 129.83, 128.90, 127.78, 
108.51, 108.24, 100.29, 63.09, 61.29, 54.02, 53.27; MS: m/z 447 (M+1). 
5.2 Molecular modelling 
The compounds in Figure 39 were drawn in Maestro (v. 9.8) and the structures were energy 
minimized using the OPLS2005 force field implemented in the Macromodel package. All molecular 
modelling calculations were performed using the software Autodock (v. 4.2.1), Glide (v. 5.6), Gold 
(v. 5.0.1) and FRED (v. 2.2.5) running on a Linux x86_64 workstation. The conformation of  
colchicine and podophyllotoxin structures were taken from the tubulin-ligand complex filed in the 
Brookhaven Protein Data Bank (entry code 1SA0 and 1SA1). The protein complexes were prepared 
for docking with Maestro/Macromodel (v. 9.1.207) Protein Preparation Wizard where bond orders 
were assigned, hydrogens added, water molecules removed, hydrogen bonds optimized and finally 
the protein energy minimized (convergence threshold 0.30 kcal/mol). The native ligand was 
redocked into the processed protein to verify that the program in use could identify the correct 
binding mode of the ligand. All molecular images were prepared with Pymol (v. 1.3).  
5.2.1 Coordinate scan 
A coordinate scan was performed in gas phase with Maestro/Macromodel using OPLS2005 as the 
force field. The method used was Powell-Reeves conjugate gradient (PRCG) with maximum 
iterations 10000, that converged on gradient with a convergence threshold of 0.0001 kj/mol. The 
energy was calculated at different A-ring/triazole and B-ring/triazole dihedral angles. The dihedral 
angle 1 was scanned from -60 – 300 degrees with 5 degrees increments. The dihedral angle 2 was 
scanned from 20 – 200 degrees with 5 degrees increments. The results are summarized in Table 9. 
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Table 9 The inversion barriers of the 1,5-disubstituted 1,2,3-triazole analogues. The 1 and 2 are the angles from the 
lowest energy configuration. The 4-methoxy group was within van der Waals distance from the π electrons of the B-
ring. 
Compound Distance 4-methoxy to centre of B-ring Å 1 2 
Inversion energy 
kcal/mol 
19  4.47 31° 50° 6.4 
20  4.54 33° 43° 4.1 
178 4.81 52° 77° 9.2 
180 4.39 41° 62° 9.7 
193 4.49 44° 50° 4.3 
192 4.49 51° 52° 4.2 
194 4.45 42° 59° 8.5 
195 4.27 41° 57° 8.9 
196 4.57 45° 48° 4.4 
297 4.42 43° 69° 4.3 
 
5.2.2 Glide 
Standard parameters were used for the grid generation with Glide. A mesh of 0.375 Å and 56 × 60 × 
50 number of points were used to generate the grid. The grid was centred on the mass centre of the 
ligand coordinates. Docking in Glide was performed with standard parameters in standard precision 
mode. 10 poses per ligand were generated. As a standard of comparison both CA-1 (19) and CA-4 
(20) and the 1,5-disubstituted-1,2,3-triazole amino analogue of CA-4 193 was docked together with 
the set of analogues. 
5.2.3 FRED 
The ligands were converted to the .oeb format with Omega2. The receptor grid was generated with 
Vida (v. 4.0.3) with a mesh of 0.375 Å and 56 × 60 × 50 number of points were used for the grid 
size. A total of six docking poses were generated and scored with Chemgauss3. 
5.2.4 Gold 
Receptor grid generation was performed with Gold and standard parameters were used to generate 
the grid with a mesh of 0.375 Å and 56 × 60 × 50 number of points for the grid size. GA was set to 
200% for the docking of the ligands and a maximum of 100 poses were generated. 
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5.2.5 Autodock4 
A mesh of 0.375 Å and 56 × 60 × 50 number of points were used to generate the grid with Autogrid. 
The grid was centred on the mass centre of the ligand coordinates. For the docking the following 
parameter values were specified: maximum number of energy evaluations: 2500000, translation 
step/A: 1.0, quaternion step/deg: 25.0 torsion step/deg: 25.0. 100 poses were generated for each 
ligand. 
5.2.6 Energy minimization 
The result complexes from the Glide docking were energy minimized with Macromodel after the 
reinsertion of GDP and GTP that were removed with the protein preparation wizard. Minimizations 
were preformed using OPLS2005 as a force field (FF) in water phase. The method used was PRCG 
with maximum iterations 30000, which converged on gradient with a convergence threshold of 0.01 
kj/mol. 
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Table 10 Docking scores 
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